ID   NLRP3_HUMAN             Reviewed;        1036 AA.
AC   Q96P20; A0A024R5Q0; B2RC97; B7ZKS9; B7ZKT2; B7ZKT3; O75434; Q17RS2; Q59H68;
AC   Q5JQS8; Q5JQS9; Q6TG35; Q8TCW0; Q8TEU9; Q8WXH9;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   03-NOV-2009, sequence version 3.
DT   08-NOV-2023, entry version 222.
DE   RecName: Full=NACHT, LRR and PYD domains-containing protein 3 {ECO:0000305};
DE            EC=3.6.4.- {ECO:0000269|PubMed:17483456, ECO:0000269|PubMed:31086327, ECO:0000269|PubMed:31086329};
DE   AltName: Full=Angiotensin/vasopressin receptor AII/AVP-like;
DE   AltName: Full=Caterpiller protein 1.1 {ECO:0000303|PubMed:14662828};
DE            Short=CLR1.1 {ECO:0000303|PubMed:14662828};
DE   AltName: Full=Cold-induced autoinflammatory syndrome 1 protein {ECO:0000303|PubMed:11687797};
DE   AltName: Full=Cryopyrin {ECO:0000303|PubMed:14662828};
DE   AltName: Full=PYRIN-containing APAF1-like protein 1 {ECO:0000303|PubMed:11786556};
GN   Name=NLRP3 {ECO:0000303|PubMed:17907925, ECO:0000312|HGNC:HGNC:16400};
GN   Synonyms=C1orf7 {ECO:0000312|HGNC:HGNC:16400}, CIAS1
GN   {ECO:0000303|PubMed:11687797}, NALP3 {ECO:0000303|PubMed:12355493},
GN   PYPAF1 {ECO:0000303|PubMed:11786556};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), VARIANTS FCAS1
RP   MET-200; VAL-441 AND GLY-629, AND VARIANT MWS VAL-354.
RX   PubMed=11687797; DOI=10.1038/ng756;
RA   Hoffman H.M., Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D.;
RT   "Mutation of a new gene encoding a putative pyrin-like protein causes
RT   familial cold autoinflammatory syndrome and Muckle-Wells syndrome.";
RL   Nat. Genet. 29:301-305(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), VARIANT MWS MET-200, AND
RP   VARIANTS FCAS1/MWS TRP-262 AND PRO-307.
RX   PubMed=12355493; DOI=10.1002/art.10509;
RA   Aganna E., Martinon F., Hawkins P.N., Ross J.B., Swan D.C., Booth D.R.,
RA   Lachmann H.J., Gaudet R., Woo P., Feighery C., Cotter F.E., Thome M.,
RA   Hitman G.A., Tschopp J., McDermott M.F.;
RT   "Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad
RT   phenotype including recurrent fever, cold sensitivity, sensorineural
RT   deafness, and AA amyloidosis.";
RL   Arthritis Rheum. 46:2445-2452(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), INTERACTION WITH PYCARD,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND AUTOINHIBITION.
RX   PubMed=11786556; DOI=10.1074/jbc.m112208200;
RA   Manji G.A., Wang L., Geddes B.J., Brown M., Merriam S., Al-Garawi A.,
RA   Mak S., Lora J.M., Briskin M., Jurman M., Cao J., DiStefano P.S.,
RA   Bertin J.;
RT   "PYPAF1: a PYRIN-containing APAF1-like protein that assembles with ASC and
RT   activates NF-kB.";
RL   J. Biol. Chem. 277:11570-11575(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 4 AND 6).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-1036 (ISOFORM 4), ALTERNATIVE SPLICING
RP   (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, AND INDUCTION BY LPS; LTA;
RP   POLY(I:C) AND TNF.
RX   PubMed=14662828; DOI=10.4049/jimmunol.171.12.6329;
RA   O'Connor W. Jr., Harton J.A., Zhu X., Linhoff M.W., Ting J.-P.;
RT   "CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory
RT   mediator with NF-kappa B suppressive properties.";
RL   J. Immunol. 171:6329-6333(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 393-1036 (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for 300
RT   previously undefined genes expressed in CD34+ hematopoietic stem/progenitor
RT   cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [11]
RP   IDENTIFICATION OF NRLP3 INFLAMMASOME COMPLEX.
RX   PubMed=15030775; DOI=10.1016/s1074-7613(04)00046-9;
RA   Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N.,
RA   Tschopp J.;
RT   "NALP3 forms an IL-1beta-processing inflammasome with increased activity in
RT   Muckle-Wells autoinflammatory disorder.";
RL   Immunity 20:319-325(2004).
RN   [12]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=16407889; DOI=10.1038/nature04516;
RA   Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J.;
RT   "Gout-associated uric acid crystals activate the NALP3 inflammasome.";
RL   Nature 440:237-241(2006).
RN   [13]
RP   INTERACTION WITH MEFV.
RX   PubMed=17431422; DOI=10.1038/sj.cdd.4402142;
RA   Papin S., Cuenin S., Agostini L., Martinon F., Werner S., Beer H.D.,
RA   Grutter C., Grutter M., Tschopp J.;
RT   "The SPRY domain of Pyrin, mutated in familial Mediterranean fever
RT   patients, interacts with inflammasome components and inhibits proIL-1beta
RT   processing.";
RL   Cell Death Differ. 14:1457-1466(2007).
RN   [14]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17164409; DOI=10.1369/jhc.6a7101.2006;
RA   Kummer J.A., Broekhuizen R., Everett H., Agostini L., Kuijk L.,
RA   Martinon F., van Bruggen R., Tschopp J.;
RT   "Inflammasome components NALP 1 and 3 Show distinct but separate expression
RT   profiles in human tissues suggesting a site-specific role in the
RT   inflammatory response.";
RL   J. Histochem. Cytochem. 55:443-452(2007).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF 231-GLY--THR-233.
RX   PubMed=17483456; DOI=10.1073/pnas.0611496104;
RA   Duncan J.A., Bergstralh D.T., Wang Y., Willingham S.B., Ye Z.,
RA   Zimmermann A.G., Ting J.P.;
RT   "Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to
RT   mediate inflammatory signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8041-8046(2007).
RN   [16]
RP   TISSUE SPECIFICITY, AND INDUCTION BY SALMONELLA.
RX   PubMed=17907925; DOI=10.1359/jbmr.071002;
RA   McCall S.H., Sahraei M., Young A.B., Worley C.S., Duncan J.A., Ting J.P.,
RA   Marriott I.;
RT   "Osteoblasts express NLRP3, a nucleotide-binding domain and leucine-rich
RT   repeat region containing receptor implicated in bacterially induced cell
RT   death.";
RL   J. Bone Miner. Res. 23:30-40(2008).
RN   [17]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=18604214; DOI=10.1038/ni.1631;
RA   Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L.,
RA   Fitzgerald K.A., Latz E.;
RT   "Silica crystals and aluminum salts activate the NALP3 inflammasome through
RT   phagosomal destabilization.";
RL   Nat. Immunol. 9:847-856(2008).
RN   [18]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=18403674; DOI=10.1126/science.1156995;
RA   Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T.,
RA   Tschopp J.;
RT   "Innate immune activation through Nalp3 inflammasome sensing of asbestos
RT   and silica.";
RL   Science 320:674-677(2008).
RN   [19]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=19414800; DOI=10.4049/jimmunol.0802696;
RA   Duncan J.A., Gao X., Huang M.T., O'Connor B.P., Thomas C.E.,
RA   Willingham S.B., Bergstralh D.T., Jarvis G.A., Sparling P.F., Ting J.P.;
RT   "Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the
RT   signaling activities of the NLRP3 and ASC-containing inflammasome.";
RL   J. Immunol. 182:6460-6469(2009).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21124315; DOI=10.1038/nature09663;
RA   Zhou R., Yazdi A.S., Menu P., Tschopp J.;
RT   "A role for mitochondria in NLRP3 inflammasome activation.";
RL   Nature 469:221-225(2011).
RN   [21]
RP   UBIQUITINATION.
RX   PubMed=22948162; DOI=10.1074/jbc.m112.407130;
RA   Juliana C., Fernandes-Alnemri T., Kang S., Farias A., Qin F., Alnemri E.S.;
RT   "Non-transcriptional priming and deubiquitination regulate NLRP3
RT   inflammasome activation.";
RL   J. Biol. Chem. 287:36617-36622(2012).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH EIF2AK2.
RX   PubMed=22801494; DOI=10.1038/nature11290;
RA   Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P.,
RA   Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y.,
RA   Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U.,
RA   Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.;
RT   "Novel role of PKR in inflammasome activation and HMGB1 release.";
RL   Nature 488:670-674(2012).
RN   [23]
RP   INTERACTION WITH GBP5, AND MUTAGENESIS OF 22-LEU-LYS-23.
RX   PubMed=22461501; DOI=10.1126/science.1217141;
RA   Shenoy A.R., Wellington D.A., Kumar P., Kassa H., Booth C.J., Cresswell P.,
RA   MacMicking J.D.;
RT   "GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals.";
RL   Science 336:481-485(2012).
RN   [24]
RP   INTERACTION WITH PML.
RX   PubMed=23430110; DOI=10.1182/blood-2012-05-432104;
RA   Lo Y.H., Huang Y.W., Wu Y.H., Tsai C.S., Lin Y.C., Mo S.T., Kuo W.C.,
RA   Chuang Y.T., Jiang S.T., Shih H.M., Lai M.Z.;
RT   "Selective inhibition of the NLRP3 inflammasome by targeting to
RT   promyelocytic leukemia protein in mouse and human.";
RL   Blood 121:3185-3194(2013).
RN   [25]
RP   REVIEW.
RX   PubMed=23305783; DOI=10.1016/j.coi.2012.12.004;
RA   Haneklaus M., O'Neill L.A., Coll R.C.;
RT   "Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation:
RT   recent developments.";
RL   Curr. Opin. Immunol. 25:40-45(2013).
RN   [26]
RP   FUNCTION, INTERACTION WITH DHX33, AND SUBCELLULAR LOCATION.
RX   PubMed=23871209; DOI=10.1016/j.immuni.2013.07.001;
RA   Mitoma H., Hanabuchi S., Kim T., Bao M., Zhang Z., Sugimoto N., Liu Y.J.;
RT   "The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3
RT   inflammasome.";
RL   Immunity 39:123-135(2013).
RN   [27]
RP   INTERACTION WITH ARRB2.
RX   PubMed=23809162; DOI=10.1016/j.immuni.2013.05.015;
RA   Yan Y., Jiang W., Spinetti T., Tardivel A., Castillo R., Bourquin C.,
RA   Guarda G., Tian Z., Tschopp J., Zhou R.;
RT   "Omega-3 fatty acids prevent inflammation and metabolic disorder through
RT   inhibition of NLRP3 inflammasome activation.";
RL   Immunity 38:1154-1163(2013).
RN   [28]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH MAVS, AND MUTAGENESIS OF
RP   2-LYS--ARG-7.
RX   PubMed=23582325; DOI=10.1016/j.cell.2013.02.054;
RA   Subramanian N., Natarajan K., Clatworthy M.R., Wang Z., Germain R.N.;
RT   "The adaptor MAVS promotes NLRP3 mitochondrial localization and
RT   inflammasome activation.";
RL   Cell 153:348-361(2013).
RN   [29]
RP   INDUCTION BY ENDOCANNABINOID ANANDAMIDE.
RX   PubMed=23955712; DOI=10.1038/nm.3265;
RA   Jourdan T., Godlewski G., Cinar R., Bertola A., Szanda G., Liu J., Tam J.,
RA   Han T., Mukhopadhyay B., Skarulis M.C., Ju C., Aouadi M., Czech M.P.,
RA   Kunos G.;
RT   "Activation of the Nlrp3 inflammasome in infiltrating macrophages by
RT   endocannabinoids mediates beta cell loss in type 2 diabetes.";
RL   Nat. Med. 19:1132-1140(2013).
RN   [30]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=23229815; DOI=10.1136/thoraxjnl-2012-202182;
RA   Triantafilou K., Kar S., Vakakis E., Kotecha S., Triantafilou M.;
RT   "Human respiratory syncytial virus viroporin SH: a viral recognition
RT   pathway used by the host to signal inflammasome activation.";
RL   Thorax 68:66-75(2013).
RN   [31]
RP   INTERACTION WITH CARD8.
RX   PubMed=24517500; DOI=10.1186/ar4483;
RA   Ito S., Hara Y., Kubota T.;
RT   "CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in
RT   cryopyrin-associated periodic syndromes escapes the restriction.";
RL   Arthritis Res. Ther. 16:R52-R52(2014).
RN   [32]
RP   MECHANISM OF INFLAMMASOME ASSEMBLY, AND MUTAGENESIS OF GLU-15; LYS-23;
RP   LYS-24; MET-27; ARG-43; GLU-64 AND ASP-82.
RX   PubMed=24630722; DOI=10.1016/j.cell.2014.02.008;
RA   Lu A., Magupalli V.G., Ruan J., Yin Q., Atianand M.K., Vos M.R.,
RA   Schroder G.F., Fitzgerald K.A., Wu H., Egelman E.H.;
RT   "Unified polymerization mechanism for the assembly of ASC-dependent
RT   inflammasomes.";
RL   Cell 156:1193-1206(2014).
RN   [33]
RP   PHOSPHORYLATION.
RX   PubMed=24623131; DOI=10.4049/jimmunol.1301974;
RA   Ghonime M.G., Shamaa O.R., Das S., Eldomany R.A., Fernandes-Alnemri T.,
RA   Alnemri E.S., Gavrilin M.A., Wewers M.D.;
RT   "Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling
RT   and proteasome function.";
RL   J. Immunol. 192:3881-3888(2014).
RN   [34]
RP   INTERACTION WITH M.PNEUMONIAE CARDS TOXIN, SUBCELLULAR LOCATION, AND
RP   PROBABLE ADP-RIBOSYLATION (MICROBIAL INFECTION).
RX   PubMed=25538194; DOI=10.1128/mbio.02186-14;
RA   Bose S., Segovia J.A., Somarajan S.R., Chang T.H., Kannan T.R.,
RA   Baseman J.B.;
RT   "ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae CARDS toxin regulates
RT   inflammasome activity.";
RL   MBio 5:0-0(2014).
RN   [35]
RP   INTERACTION WITH PYDC5.
RX   PubMed=24531343; DOI=10.1038/ni.2829;
RA   Khare S., Ratsimandresy R.A., de Almeida L., Cuda C.M., Rellick S.L.,
RA   Misharin A.V., Wallin M.C., Gangopadhyay A., Forte E., Gottwein E.,
RA   Perlman H., Reed J.C., Greaves D.R., Dorfleutner A., Stehlik C.;
RT   "The PYRIN domain-only protein POP3 inhibits ALR inflammasomes and
RT   regulates responses to infection with DNA viruses.";
RL   Nat. Immunol. 15:343-353(2014).
RN   [36]
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT FCAS1/MWS TRP-262,
RP   CHARACTERIZATION OF VARIANT CINCA ASN-305, AND CHARACTERIZATION OF VARIANT
RP   CINCA/MWS MET-350.
RX   PubMed=24952504; DOI=10.1038/ni.2919;
RA   Baroja-Mazo A., Martin-Sanchez F., Gomez A.I., Martinez C.M.,
RA   Amores-Iniesta J., Compan V., Barbera-Cremades M., Yaguee J.,
RA   Ruiz-Ortiz E., Anton J., Bujan S., Couillin I., Brough D., Arostegui J.I.,
RA   Pelegrin P.;
RT   "The NLRP3 inflammasome is released as a particulate danger signal that
RT   amplifies the inflammatory response.";
RL   Nat. Immunol. 15:738-748(2014).
RN   [37]
RP   REVIEW ON INFLAMMASOME ASSEMBLY.
RX   PubMed=25354325; DOI=10.1111/febs.13133;
RA   Lu A., Wu H.;
RT   "Structural mechanisms of inflammasome assembly.";
RL   FEBS J. 282:435-444(2015).
RN   [38]
RP   UBIQUITINATION AT LYS-689, AND MUTAGENESIS OF TRP-68; TRP-73 AND LYS-689.
RX   PubMed=26037928; DOI=10.1074/jbc.m115.645549;
RA   Han S., Lear T.B., Jerome J.A., Rajbhandari S., Snavely C.A., Gulick D.L.,
RA   Gibson K.F., Zou C., Chen B.B., Mallampalli R.K.;
RT   "Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its
RT   ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase.";
RL   J. Biol. Chem. 290:18124-18133(2015).
RN   [39]
RP   INTERACTION WITH MEFV.
RX   PubMed=26347139; DOI=10.1083/jcb.201503023;
RA   Kimura T., Jain A., Choi S.W., Mandell M.A., Schroder K., Johansen T.,
RA   Deretic V.;
RT   "TRIM-mediated precision autophagy targets cytoplasmic regulators of innate
RT   immunity.";
RL   J. Cell Biol. 210:973-989(2015).
RN   [40]
RP   FUNCTION, UBIQUITINATION, AND MUTAGENESIS OF SER-198.
RX   PubMed=27929086; DOI=10.1038/ncomms13727;
RA   Song H., Liu B., Huai W., Yu Z., Wang W., Zhao J., Han L., Jiang G.,
RA   Zhang L., Gao C., Zhao W.;
RT   "The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by
RT   promoting proteasomal degradation of NLRP3.";
RL   Nat. Commun. 7:13727-13727(2016).
RN   [41]
RP   PHOSPHORYLATION AT TYR-13; SER-163; SER-198; SER-334; SER-728 AND SER-975.
RX   PubMed=28943315; DOI=10.1016/j.molcel.2017.08.017;
RA   Song N., Liu Z.S., Xue W., Bai Z.F., Wang Q.Y., Dai J., Liu X., Huang Y.J.,
RA   Cai H., Zhan X.Y., Han Q.Y., Wang H., Chen Y., Li H.Y., Li A.L.,
RA   Zhang X.M., Zhou T., Li T.;
RT   "NLRP3 phosphorylation is an essential priming event for inflammasome
RT   activation.";
RL   Mol. Cell 68:185-197(2017).
RN   [42]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH MARK4, AND MUTAGENESIS OF
RP   VAL-52.
RX   PubMed=28656979; DOI=10.1038/ncomms15986;
RA   Li X., Thome S., Ma X., Amrute-Nayak M., Finigan A., Kitt L., Masters L.,
RA   James J.R., Shi Y., Meng G., Mallat Z.;
RT   "MARK4 regulates NLRP3 positioning and inflammasome activation through a
RT   microtubule-dependent mechanism.";
RL   Nat. Commun. 8:15986-15986(2017).
RN   [43]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=25686105; DOI=10.1038/nm.3806;
RA   Coll R.C., Robertson A.A., Chae J.J., Higgins S.C., Munoz-Planillo R.,
RA   Inserra M.C., Vetter I., Dungan L.S., Monks B.G., Stutz A., Croker D.E.,
RA   Butler M.S., Haneklaus M., Sutton C.E., Nunez G., Latz E., Kastner D.L.,
RA   Mills K.H., Masters S.L., Schroder K., Cooper M.A., O'Neill L.A.;
RT   "A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of
RT   inflammatory diseases.";
RL   Nat. Med. 21:248-255(2015).
RN   [44]
RP   PHOSPHORYLATION AT TYR-861, AND MUTAGENESIS OF TYR-861.
RX   PubMed=27043286; DOI=10.1172/jci83669;
RA   Spalinger M.R., Kasper S., Gottier C., Lang S., Atrott K., Vavricka S.R.,
RA   Scharl S., Raselli T., Frey-Wagner I., Gutte P.M., Gruetter M.G.,
RA   Beer H.D., Contassot E., Chan A.C., Dai X., Rawlings D.J., Mair F.,
RA   Becher B., Falk W., Fried M., Rogler G., Scharl M.;
RT   "NLRP3 tyrosine phosphorylation is controlled by protein tyrosine
RT   phosphatase PTPN22.";
RL   J. Clin. Invest. 126:1783-1800(2016).
RN   [45]
RP   PHOSPHORYLATION AT SER-5, 7ACTIVITY REGULATION, AND MUTAGENESIS OF SER-5
RP   AND 7-ARG--ARG-12.
RX   PubMed=28465465; DOI=10.1084/jem.20160933;
RA   Stutz A., Kolbe C.C., Stahl R., Horvath G.L., Franklin B.S., van Ray O.,
RA   Brinkschulte R., Geyer M., Meissner F., Latz E.;
RT   "NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin
RT   domain.";
RL   J. Exp. Med. 214:1725-1736(2017).
RN   [46]
RP   FUNCTION, INVOLVEMENT IN DFNA34, VARIANT DFNA34 GLN-920, AND
RP   CHARACTERIZATION OF VARIANT DFNA34 GLN-920.
RX   PubMed=28847925; DOI=10.1073/pnas.1702946114;
RA   Nakanishi H., Kawashima Y., Kurima K., Chae J.J., Ross A.M.,
RA   Pinto-Patarroyo G., Patel S.K., Muskett J.A., Ratay J.S., Chattaraj P.,
RA   Park Y.H., Grevich S., Brewer C.C., Hoa M., Kim H.J., Butman J.A.,
RA   Broderick L., Hoffman H.M., Aksentijevich I., Kastner D.L.,
RA   Goldbach-Mansky R., Griffith A.J.;
RT   "mutation and cochlear autoinflammation cause syndromic and nonsyndromic
RT   hearing loss DFNA34 responsive to anakinra therapy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E7766-E7775(2017).
RN   [47]
RP   FUNCTION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=30487600; DOI=10.1038/s41586-018-0761-3;
RA   Chen J., Chen Z.J.;
RT   "PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome
RT   activation.";
RL   Nature 564:71-76(2018).
RN   [48]
RP   FUNCTION, ACTIVITY REGULATION, INTERACTION WITH IRGM, AND PROTEIN
RP   DEGRADATION.
RX   PubMed=30612879; DOI=10.1016/j.molcel.2018.11.018;
RA   Mehto S., Jena K.K., Nath P., Chauhan S., Kolapalli S.P., Das S.K.,
RA   Sahoo P.K., Jain A., Taylor G.A., Chauhan S.;
RT   "The Crohn's disease risk factor IRGM limits NLRP3 inflammasome activation
RT   by impeding its assembly and by mediating its selective autophagy.";
RL   Mol. Cell 73:429-445(2019).
RN   [49]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   231-GLY--THR-233 AND 302-ASP--GLU-306.
RX   PubMed=31086327; DOI=10.1038/s41589-019-0277-7;
RA   Coll R.C., Hill J.R., Day C.J., Zamoshnikova A., Boucher D., Massey N.L.,
RA   Chitty J.L., Fraser J.A., Jennings M.P., Robertson A.A.B., Schroder K.;
RT   "MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome
RT   inhibition.";
RL   Nat. Chem. Biol. 15:556-559(2019).
RN   [50]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, MUTAGENESIS OF
RP   302-ASP--GLU-306, AND CHARACTERIZATION OF VARIANT CINCA ASN-305.
RX   PubMed=31086329; DOI=10.1038/s41589-019-0278-6;
RA   Tapia-Abellan A., Angosto-Bazarra D., Martinez-Banaclocha H.,
RA   de Torre-Minguela C., Ceron-Carrasco J.P., Perez-Sanchez H.,
RA   Arostegui J.I., Pelegrin P.;
RT   "MCC950 closes the active conformation of NLRP3 to an inactive state.";
RL   Nat. Chem. Biol. 15:560-564(2019).
RN   [51]
RP   FUNCTION, INDUCTION BY SARS-COV-2 INFECTION, ACTIVITY REGULATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=34133077; DOI=10.15252/emmm.202114150;
RA   Theobald S.J., Simonis A., Georgomanolis T., Kreer C., Zehner M.,
RA   Eisfeld H.S., Albert M.C., Chhen J., Motameny S., Erger F., Fischer J.,
RA   Malin J.J., Graeb J., Winter S., Pouikli A., David F., Boell B.,
RA   Koehler P., Vanshylla K., Gruell H., Suarez I., Hallek M., Faetkenheuer G.,
RA   Jung N., Cornely O.A., Lehmann C., Tessarz P., Altmueller J., Nuernberg P.,
RA   Kashkar H., Klein F., Koch M., Rybniker J.;
RT   "Long-lived macrophage reprogramming drives spike protein-mediated
RT   inflammasome activation in COVID-19.";
RL   EMBO Mol. Med. 0:0-0(2021).
RN   [52]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=33231615; DOI=10.1084/jem.20201707;
RA   Rodrigues T.S., de Sa K.S.G., Ishimoto A.Y., Becerra A., Oliveira S.,
RA   Almeida L., Goncalves A.V., Perucello D.B., Andrade W.A., Castro R.,
RA   Veras F.P., Toller-Kawahisa J.E., Nascimento D.C., de Lima M.H.F.,
RA   Silva C.M.S., Caetite D.B., Martins R.B., Castro I.A., Pontelli M.C.,
RA   de Barros F.C., do Amaral N.B., Giannini M.C., Bonjorno L.P., Lopes M.I.F.,
RA   Santana R.C., Vilar F.C., Auxiliadora-Martins M., Luppino-Assad R.,
RA   de Almeida S.C.L., de Oliveira F.R., Batah S.S., Siyuan L., Benatti M.N.,
RA   Cunha T.M., Alves-Filho J.C., Cunha F.Q., Cunha L.D., Frantz F.G.,
RA   Kohlsdorf T., Fabro A.T., Arruda E., de Oliveira R.D.R., Louzada-Junior P.,
RA   Zamboni D.S.;
RT   "Inflammasomes are activated in response to SARS-CoV-2 infection and are
RT   associated with COVID-19 severity in patients.";
RL   J. Exp. Med. 218:0-0(2021).
RN   [53]
RP   FUNCTION, INTERACTION WITH SARS-COV-2 N PROTEIN (MICROBIAL INFECTION), AND
RP   INTERACTION WITH PYCARD.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   "SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation.";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [54]
RP   FUNCTION, PHOSPHORYLATION AT TYR-136; TYR-140; TYR-143 AND TYR-168, AND
RP   MUTAGENESIS OF 136-TYR--TYR-143 AND TYR-168.
RX   PubMed=34554188; DOI=10.1084/jem.20201656;
RA   Bittner Z.A., Liu X., Mateo Tortola M., Tapia-Abellan A., Shankar S.,
RA   Andreeva L., Mangan M., Spalinger M., Kalbacher H., Duewell P., Lovotti M.,
RA   Bosch K., Dickhoefer S., Marcu A., Stevanovic S., Herster F.,
RA   Cardona Gloria Y., Chang T.H., Bork F., Greve C.L., Loeffler M.W.,
RA   Wolz O.O., Schilling N.A., Kuemmerle-Deschner J.B., Wagner S., Delor A.,
RA   Grimbacher B., Hantschel O., Scharl M., Wu H., Latz E., Weber A.N.R.;
RT   "BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome
RT   activity.";
RL   J. Exp. Med. 218:0-0(2021).
RN   [55]
RP   PHOSPHORYLATION AT SER-735; SER-806 AND SER-1035, UBIQUITINATION AT
RP   LYS-878; LYS-927 AND LYS-973, AND MUTAGENESIS OF SER-735; SER-806 AND
RP   SER-1035.
RX   PubMed=34615873; DOI=10.1038/s41467-021-26142-w;
RA   Niu T., De Rosny C., Chautard S., Rey A., Patoli D., Groslambert M.,
RA   Cosson C., Lagrange B., Zhang Z., Visvikis O., Hacot S., Hologne M.,
RA   Walker O., Wong J., Wang P., Ricci R., Henry T., Boyer L., Petrilli V.,
RA   Py B.F.;
RT   "NLRP3 phosphorylation in its LRR domain critically regulates inflammasome
RT   assembly.";
RL   Nat. Commun. 12:5862-5862(2021).
RN   [56]
RP   FUNCTION, AND UBIQUITINATION BY TRIM65.
RX   PubMed=34512673; DOI=10.3389/fimmu.2021.741839;
RA   Tang T., Li P., Zhou X., Wang R., Fan X., Yang M., Qi K.;
RT   "The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome
RT   Activation Through Promoting Ubiquitination of NLRP3.";
RL   Front. Immunol. 12:741839-741839(2021).
RN   [57]
RP   DOMAIN.
RX   PubMed=34524838; DOI=10.1126/sciadv.abf4468;
RA   Tapia-Abellan A., Angosto-Bazarra D., Alarcon-Vila C., Banos M.C.,
RA   Hafner-Bratkovic I., Oliva B., Pelegrin P.;
RT   "Sensing low intracellular potassium by NLRP3 results in a stable open
RT   structure that promotes inflammasome activation.";
RL   Sci. Adv. 7:eabf4468-eabf4468(2021).
RN   [58]
RP   PALMITOYLATION AT CYS-844, INTERACTION WITH HSPA8, AND MUTAGENESIS OF
RP   GLN-359; GLN-603; GLN-798; CYS-844 AND GLN-995.
RX   PubMed=36586411; DOI=10.1016/j.molcel.2022.12.002;
RA   Wang L., Cai J., Zhao X., Ma L., Zeng P., Zhou L., Liu Y., Yang S., Cai Z.,
RA   Zhang S., Zhou L., Yang J., Liu T., Jin S., Cui J.;
RT   "Palmitoylation prevents sustained inflammation by limiting NLRP3
RT   inflammasome activation through chaperone-mediated autophagy.";
RL   Mol. Cell 0:0-0(2022).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3-112, SUBUNIT, AND DISULFIDE
RP   BOND.
RX   PubMed=21880711; DOI=10.1074/jbc.m111.278812;
RA   Bae J.Y., Park H.H.;
RT   "Crystal structure of NALP3 protein pyrin domain (PYD) and its implications
RT   in inflammasome assembly.";
RL   J. Biol. Chem. 286:39528-39536(2011).
RN   [60] {ECO:0007744|PDB:2NAQ}
RP   STRUCTURE BY NMR OF 3-93, FUNCTION, ACTIVITY REGULATION, AND INTERACTION
RP   WITH PYCARD.
RX   PubMed=27432880; DOI=10.1074/jbc.m116.741082;
RA   Oroz J., Barrera-Vilarmau S., Alfonso C., Rivas G., de Alba E.;
RT   "ASC pyrin domain self-associates and binds NLRP3 protein using equivalent
RT   binding interfaces.";
RL   J. Biol. Chem. 291:19487-19501(2016).
RN   [61] {ECO:0007744|PDB:6NPY}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.80 ANGSTROMS) OF 3-1036 IN COMPLEX WITH
RP   NEK7, FUNCTION, INTERACTION WITH NEK7, AND MUTAGENESIS OF GLN-359;
RP   638-GLN--GLU-640; VAL-707; GLU-745; ASP-750; GLU-802; TRP-833; GLU-864 AND
RP   TYR-918.
RX   PubMed=31189953; DOI=10.1038/s41586-019-1295-z;
RA   Sharif H., Wang L., Wang W.L., Magupalli V.G., Andreeva L., Qiao Q.,
RA   Hauenstein A.V., Wu Z., Nunez G., Mao Y., Wu H.;
RT   "Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome.";
RL   Nature 570:338-343(2019).
RN   [62] {ECO:0007744|PDB:7ALV}
RP   X-RAY CRYSTALLOGRAPHY (2.83 ANGSTROMS) OF 131-679 IN COMPLEX WITH ADP AND
RP   SMALL-MOLECULE INHIBITOR, AND ACTIVITY REGULATION.
RX   PubMed=34687713; DOI=10.1016/j.jmb.2021.167309;
RA   Dekker C., Mattes H., Wright M., Boettcher A., Hinniger A., Hughes N.,
RA   Kapps-Fouthier S., Eder J., Erbel P., Stiefl N., Mackay A., Farady C.J.;
RT   "Crystal structure of NLRP3 NACHT domain with an inhibitor defines
RT   mechanism of inflammasome inhibition.";
RL   J. Mol. Biol. 433:167309-167309(2021).
RN   [63] {ECO:0007744|PDB:7PZC}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.90 ANGSTROMS) IN COMPLEX WITH ADP AND
RP   INHIBITOR MCC950, SUBUNIT, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-198
RP   AND SER-201, AND MUTAGENESIS OF ALA-228; ARG-351; ARG-578;
RP   619-LYS--LEU-621; 689-LYS--GLY-698; 788-PHE-ASP-789 AND LYS-831.
RX   PubMed=35114687; DOI=10.1038/s41586-022-04467-w;
RA   Hochheiser I.V., Pilsl M., Hagelueken G., Moecking J., Marleaux M.,
RA   Brinkschulte R., Latz E., Engel C., Geyer M.;
RT   "Structure of the NLRP3 decamer bound to the cytokine release inhibitor
RT   CRID3.";
RL   Nature 604:184-189(2022).
RN   [64] {ECO:0007744|PDB:7VTP}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.23 ANGSTROMS) OF 130-1036 IN COMPLEX
RP   WITH ADP AND INHIBITOR MCC950, AND ACTIVITY REGULATION.
RX   PubMed=35254907; DOI=10.1073/pnas.2121353119;
RA   Ohto U., Kamitsukasa Y., Ishida H., Zhang Z., Murakami K., Hirama C.,
RA   Maekawa S., Shimizu T.;
RT   "Structural basis for the oligomerization-mediated regulation of NLRP3
RT   inflammasome activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2121353119-e2121353119(2022).
RN   [65] {ECO:0007744|PDB:7PZD}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.60 ANGSTROMS) OF 3-110, ACTIVITY
RP   REGULATION, INTERACTION WITH PYCARD, MUTAGENESIS OF ARG-7; GLU-15;
RP   23-LYS-LYS-24; MET-27; ASP-31; ARG-43; HIS-51; ALA-77; ARG-80 AND ARG-81,
RP   AND CHARACTERIZATION OF VARIANT KEFH HIS-21.
RX   PubMed=35559676; DOI=10.1126/sciadv.abn7583;
RA   Hochheiser I.V., Behrmann H., Hagelueken G., Rodriguez-Alcazar J.F.,
RA   Kopp A., Latz E., Behrmann E., Geyer M.;
RT   "Directionality of PYD filament growth determined by the transition of
RT   NLRP3 nucleation seeds to ASC elongation.";
RL   Sci. Adv. 8:eabn7583-eabn7583(2022).
RN   [66] {ECO:0007744|PDB:7ZGU}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.40 ANGSTROMS) OF 126-1036 IN COMPLEX
RP   WITH ADP, FUNCTION, ACTIVITY REGULATION, INTERACTION WITH PYCARD, AND
RP   MUTAGENESIS OF TYR-143; PHE-788; ASP-789; PHE-813 AND ARG-816.
RX   PubMed=36142182; DOI=10.3390/ijms231810269;
RA   Machtens D.A., Bresch I.P., Eberhage J., Reubold T.F., Eschenburg S.;
RT   "The inflammasome activity of NLRP3 is independent of NEK7 in HEK293 cells
RT   co-expressing ASC.";
RL   Int. J. Mol. Sci. 23:0-0(2022).
RN   [67]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF 1-95 AND 133-1004 IN
RP   COMPLEX WITH ATP AND NEK7, FUNCTION, ACTIVITY REGULATION, SUBUNIT,
RP   INTERACTION WITH NEK7, DOMAIN, AND MUTAGENESIS OF ARG-147; GLU-152;
RP   ASN-155; ARG-157; LYS-166; GLU-176; ASP-213; GLN-359; HIS-364; GLN-424 AND
RP   GLN-509.
RX   PubMed=36442502; DOI=10.1038/s41586-022-05570-8;
RA   Xiao L., Magupalli V.G., Wu H.;
RT   "Cryo-EM structures of the active NLRP3 inflammasome disk.";
RL   Nature 0:0-0(2022).
RN   [68]
RP   VARIANT FCAS1 MET-200, VARIANTS MWS ASN-305; MET-350; THR-441 AND ARG-571,
RP   AND VARIANT FCAS1/MWS TRP-262.
RX   PubMed=11992256; DOI=10.1086/340786;
RA   Dode C., Le Du N., Cuisset L., Letourneur F., Berthelot J.-M., Vaudour G.,
RA   Meyrier A., Watts R.A., Scott D.G.I., Nicholls A., Granel B., Frances C.,
RA   Garcier F., Edery P., Boulinguez S., Domergues J.-P., Delpech M.,
RA   Grateau G.;
RT   "New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and
RT   familial cold urticaria: a novel mutation underlies both syndromes.";
RL   Am. J. Hum. Genet. 70:1498-1506(2002).
RN   [69]
RP   VARIANTS CINCA ASN-305; LYS-308; SER-311; ARG-360; ASN-438; SER-575 AND
RP   THR-664, AND TISSUE SPECIFICITY.
RX   PubMed=12032915; DOI=10.1086/341357;
RA   Feldmann J., Prieur A.-M., Quartier P., Berquin P., Certain S., Cortis E.,
RA   Teillac-Hamel D., Fischer A., de Saint Basile G.;
RT   "Chronic infantile neurological cutaneous and articular syndrome is caused
RT   by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells
RT   and chondrocytes.";
RL   Am. J. Hum. Genet. 71:198-203(2002).
RN   [70]
RP   ERRATUM OF PUBMED:12032915.
RA   Feldmann J., Prieur A.-M., Quartier P., Berquin P., Certain S., Cortis E.,
RA   Teillac-Hamel D., Fischer A., de Saint Basile G.;
RL   Am. J. Hum. Genet. 71:1258-1258(2002).
RN   [71]
RP   VARIANTS CINCA HIS-266; ASN-305; LEU-525 AND CYS-572.
RX   PubMed=12483741; DOI=10.1002/art.10688;
RA   Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T.,
RA   Hofmann S.R., Stein L., Russo R., Goldsmith D., Dent P., Rosenberg H.F.,
RA   Austin F., Remmers E.F., Balow J.E. Jr., Rosenzweig S., Komarow H.,
RA   Shoham N.G., Wood G., Jones J., Mangra N., Carrero H., Adams B.S.,
RA   Moore T.L., Schikler K., Hoffman H., Lovell D.J., Lipnick R., Barron K.,
RA   O'Shea J.J., Kastner D.L., Goldbach-Mansky R.;
RT   "De novo CIAS1 mutations, cytokine activation, and evidence for genetic
RT   heterogeneity in patients with neonatal-onset multisystem inflammatory
RT   disease (NOMID): a new member of the expanding family of pyrin-associated
RT   autoinflammatory diseases.";
RL   Arthritis Rheum. 46:3340-3348(2002).
RN   [72]
RP   VARIANT FCAS1 PRO-355, AND VARIANT LYS-705.
RX   PubMed=12522564; DOI=10.1007/s00439-002-0860-x;
RA   Hoffman H.M., Gregory S.G., Mueller J.L., Tresierras M., Broide D.H.,
RA   Wanderer A.A., Kolodner R.D.;
RT   "Fine structure mapping of CIAS1: identification of an ancestral haplotype
RT   and a common FCAS mutation, L353P.";
RL   Hum. Genet. 112:209-216(2003).
RN   [73]
RP   VARIANT CINCA CYS-861.
RX   PubMed=15334500; DOI=10.1002/art.20295;
RA   Frenkel J., van Kempen M.J., Kuis W., van Amstel H.K.;
RT   "Variant chronic infantile neurologic, cutaneous, articular syndrome due to
RT   a mutation within the leucine-rich repeat domain of CIAS1.";
RL   Arthritis Rheum. 50:2719-2720(2004).
RN   [74]
RP   VARIANTS FCAS1 MET-200; PRO-307 AND LYS-490, VARIANT CINCA ASN-305, AND
RP   VARIANT MWS MET-350.
RX   PubMed=15593220; DOI=10.1002/art.20633;
RA   Arostegui J.I., Aldea A., Modesto C., Rua M.J., Argueelles F.,
RA   Gonzalez-Ensenat M.A., Ramos E., Rius J., Plaza S., Vives J., Yaguee J.;
RT   "Clinical and genetic heterogeneity among Spanish patients with recurrent
RT   autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene.";
RL   Arthritis Rheum. 50:4045-4050(2004).
RN   [75]
RP   VARIANTS CINCA LEU-262; PRO-262; ASN-305; GLY-305; SER-311; MET-350;
RP   ASP-356; PRO-407; ILE-438; CYS-572 AND PHE-634.
RX   PubMed=14630794; DOI=10.1182/blood-2003-07-2531;
RA   Neven B., Callebaut I., Prieur A.-M., Feldmann J., Bodemer C., Lepore L.,
RA   Derfalvi B., Benjaponpitak S., Vesely R., Sauvain M.J., Oertle S.,
RA   Allen R., Morgan G., Borkhardt A., Hill C., Gardner-Medwin J., Fischer A.,
RA   de Saint Basile G.;
RT   "Molecular basis of the spectral expression of CIAS1 mutations associated
RT   with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS,
RT   and FCU.";
RL   Blood 103:2809-2815(2004).
RN   [76]
RP   VARIANT CINCA THR-174.
RX   PubMed=15231984; DOI=10.1542/peds.114.1.e124;
RA   Stojanov S., Weiss M., Lohse P., Belohradsky B.H.;
RT   "A novel CIAS1 mutation and plasma/cerebrospinal fluid cytokine profile in
RT   a German patient with neonatal-onset multisystem inflammatory disease
RT   responsive to methotrexate therapy.";
RL   Pediatrics 114:E124-E127(2004).
RN   [77]
RP   VARIANT FCAS1 CYS-525.
RX   PubMed=17284928; DOI=10.1159/000099311;
RA   Shalev S.A., Sprecher E., Indelman M., Hujirat Y., Bergman R., Rottem M.;
RT   "A novel missense mutation in CIAS1 encoding the pyrin-like protein,
RT   cryopyrin, causes familial cold autoinflammatory syndrome in a family of
RT   Ethiopian origin.";
RL   Int. Arch. Allergy Immunol. 143:190-193(2007).
RN   [78]
RP   VARIANT KEFH HIS-21, AND INVOLVEMENT IN KEFH.
RX   PubMed=29366613; DOI=10.1016/j.ajo.2018.01.017;
RA   Turunen J.A., Wedenoja J., Repo P., Jaervinen R.S., Jaentti J.E.,
RA   Moertenhumer S., Riikonen A.S., Lehesjoki A.E., Majander A., Kivelae T.T.;
RT   "Keratoendotheliitis fugax hereditaria: a novel cryopyrin-associated
RT   periodic syndrome caused by a mutation in the nucleotide-binding domain,
RT   leucine-rich repeat family, pyrin domain-containing 3 (NLRP3) gene.";
RL   Am. J. Ophthalmol. 188:41-50(2018).
CC   -!- FUNCTION: Sensor component of the NLRP3 inflammasome, which mediates
CC       inflammasome activation in response to defects in membrane integrity,
CC       leading to secretion of inflammatory cytokines IL1B and IL18 and
CC       pyroptosis (PubMed:16407889, PubMed:18604214, PubMed:18403674,
CC       PubMed:23582325, PubMed:28847925, PubMed:33231615, PubMed:34133077,
CC       PubMed:34341353, PubMed:27929086, PubMed:28656979, PubMed:25686105,
CC       PubMed:30487600, PubMed:30612879, PubMed:31086327, PubMed:31086329,
CC       PubMed:31189953, PubMed:34512673, PubMed:36442502). In response to
CC       pathogens and other damage-associated signals that affect the integrity
CC       of membranes, initiates the formation of the inflammasome polymeric
CC       complex composed of NLRP3, CASP1 and PYCARD/ASC (PubMed:16407889,
CC       PubMed:18403674, PubMed:28847925, PubMed:33231615, PubMed:34133077,
CC       PubMed:34341353, PubMed:27432880, PubMed:31189953, PubMed:36142182,
CC       PubMed:36442502). Recruitment of pro-caspase-1 (proCASP1) to the NLRP3
CC       inflammasome promotes caspase-1 (CASP1) activation, which subsequently
CC       cleaves and activates inflammatory cytokines IL1B and IL18 and
CC       gasdermin-D (GSDMD), promoting cytokine secretion and pyroptosis
CC       (PubMed:23582325, PubMed:28847925, PubMed:33231615, PubMed:34133077,
CC       PubMed:34341353, PubMed:31189953). Activation of NLRP3 inflammasome is
CC       also required for HMGB1 secretion; stimulating inflammatory responses
CC       (PubMed:22801494). Under resting conditions, ADP-bound NLRP3 is
CC       autoinhibited (PubMed:35114687). NLRP3 activation stimuli include
CC       extracellular ATP, nigericin, reactive oxygen species, crystals of
CC       monosodium urate or cholesterol, amyloid-beta fibers, environmental or
CC       industrial particles and nanoparticles, such as asbestos, silica,
CC       aluminum salts, cytosolic dsRNA, etc (PubMed:16407889, PubMed:18604214,
CC       PubMed:18403674, PubMed:19414800, PubMed:23871209). Almost all stimuli
CC       trigger intracellular K(+) efflux (By similarity). These stimuli lead
CC       to membrane perturbation and activation of NLRP3 (By similarity). Upon
CC       activation, NLRP3 is transported to microtubule organizing center
CC       (MTOC), where it is unlocked by NEK7, leading to its relocalization to
CC       dispersed trans-Golgi network (dTGN) vesicle membranes and formation of
CC       an active inflammasome complex (PubMed:36442502). Associates with dTGN
CC       vesicle membranes by binding to phosphatidylinositol 4-phosphate
CC       (PtdIns4P) (PubMed:30487600, PubMed:34554188). Shows ATPase activity
CC       (PubMed:17483456). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000269|PubMed:16407889, ECO:0000269|PubMed:17483456,
CC       ECO:0000269|PubMed:18403674, ECO:0000269|PubMed:18604214,
CC       ECO:0000269|PubMed:19414800, ECO:0000269|PubMed:22801494,
CC       ECO:0000269|PubMed:23582325, ECO:0000269|PubMed:23871209,
CC       ECO:0000269|PubMed:25686105, ECO:0000269|PubMed:27432880,
CC       ECO:0000269|PubMed:27929086, ECO:0000269|PubMed:28656979,
CC       ECO:0000269|PubMed:28847925, ECO:0000269|PubMed:30487600,
CC       ECO:0000269|PubMed:30612879, ECO:0000269|PubMed:31086327,
CC       ECO:0000269|PubMed:31086329, ECO:0000269|PubMed:31189953,
CC       ECO:0000269|PubMed:33231615, ECO:0000269|PubMed:34133077,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:34554188,
CC       ECO:0000269|PubMed:35114687, ECO:0000269|PubMed:36142182,
CC       ECO:0000269|PubMed:36442502}.
CC   -!- FUNCTION: Independently of inflammasome activation, regulates the
CC       differentiation of T helper 2 (Th2) cells and has a role in Th2 cell-
CC       dependent asthma and tumor growth (By similarity). During Th2
CC       differentiation, required for optimal IRF4 binding to IL4 promoter and
CC       for IRF4-dependent IL4 transcription (By similarity). Binds to the
CC       consensus DNA sequence 5'-GRRGGNRGAG-3' (By similarity). May also
CC       participate in the transcription of IL5, IL13, GATA3, CCR3, CCR4 and
CC       MAF (By similarity). {ECO:0000250|UniProtKB:Q8R4B8}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:17483456, ECO:0000269|PubMed:31086327,
CC         ECO:0000269|PubMed:31086329};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000269|PubMed:17483456, ECO:0000269|PubMed:31086327,
CC         ECO:0000269|PubMed:31086329};
CC   -!- ACTIVITY REGULATION: Under resting conditions, NLRP3 binds ADP and is
CC       autoinhibited (PubMed:35114687). Inactive NLRP3 forms homodecameric
CC       double-ring cages that hide pyrin domains within NACHT-LRR rings to
CC       avoid premature activation (PubMed:35114687). NLRP3 activation stimuli
CC       include extracellular ATP, nigericin, reactive oxygen species, crystals
CC       of monosodium urate or cholesterol, amyloid-beta fibers, environmental
CC       or industrial particles and nanoparticles, such as asbestos, silica,
CC       aluminum salts, cytosolic dsRNA, etc (PubMed:16407889, PubMed:18604214,
CC       PubMed:18403674, PubMed:19414800, PubMed:35114687). Activated upon
CC       human coronavirus SARS-CoV-2 infection (PubMed:33231615,
CC       PubMed:34133077). Almost all stimuli trigger intracellular K(+) efflux
CC       (By similarity). These stimuli lead to membrane perturbations that
CC       induce activation of NLRP3 (By similarity). Upon activation, NLRP3 is
CC       transported to microtubule organizing center (MTOC), where it is
CC       unlocked by NEK7, leading to its relocalization to dispersed trans-
CC       Golgi network (dTGN) vesicle membranes and recruitment of PYCARD/ASC
CC       for the formation of an active inflammasome complex (PubMed:30487600,
CC       PubMed:30612879, PubMed:36442502). NEK7-activated NLRP3 forms a disk-
CC       shaped inflammasome (PubMed:36442502). NLRP3 and PYCARD/ASC interact
CC       via their respective pyrin domains; interaction initiates speck
CC       formation (nucleation) which greatly enhances further addition of
CC       soluble PYCARD/ASC molecules to the speck in a prion-like
CC       polymerization process (PubMed:24630722, PubMed:28465465,
CC       PubMed:27432880, PubMed:35559676, PubMed:36142182, PubMed:36442502).
CC       Clustered PYCARD/ASC nucleates the formation of CASP1 filaments through
CC       the interaction of their respective CARD domains, acting as a platform
CC       for CASP1 polymerization and activation (PubMed:24630722). Active CASP1
CC       then processes IL1B and IL18 precursors, leading to the release of
CC       mature cytokines in the extracellular milieu and inflammatory response
CC       (PubMed:24630722). NLRP3 inflammasome assembly is inhibited by IRGM,
CC       which impedes NLRP3 oligomerization (PubMed:30612879). Specifically
CC       inhibited by sulfonylurea MCC950 (also named CP-456,773, CRID3), a
CC       potent and specific small-molecule inhibitor of the NLRP3 inflammasome
CC       that acts by preventing ATP hydrolysis (PubMed:25686105,
CC       PubMed:31086327, PubMed:31086329, PubMed:34687713, PubMed:35114687,
CC       PubMed:35254907). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000269|PubMed:16407889, ECO:0000269|PubMed:18403674,
CC       ECO:0000269|PubMed:18604214, ECO:0000269|PubMed:19414800,
CC       ECO:0000269|PubMed:24630722, ECO:0000269|PubMed:25686105,
CC       ECO:0000269|PubMed:27432880, ECO:0000269|PubMed:28465465,
CC       ECO:0000269|PubMed:30487600, ECO:0000269|PubMed:30612879,
CC       ECO:0000269|PubMed:31086327, ECO:0000269|PubMed:31086329,
CC       ECO:0000269|PubMed:33231615, ECO:0000269|PubMed:34133077,
CC       ECO:0000269|PubMed:34687713, ECO:0000269|PubMed:35114687,
CC       ECO:0000269|PubMed:35254907, ECO:0000269|PubMed:35559676,
CC       ECO:0000269|PubMed:36142182, ECO:0000269|PubMed:36442502}.
CC   -!- SUBUNIT: Sensor component of NLRP3 inflammasomes; inflammasomes are
CC       supramolecular complexes that assemble in the cytosol in response to
CC       pathogens and other damage-associated signals and play critical roles
CC       in innate immunity and inflammation (PubMed:11786556, PubMed:15030775,
CC       PubMed:21880711). The core of NLRP3 inflammasomes consists of a signal
CC       sensor component (NLRP3), an adapter (PYCARD/ASC), which recruits an
CC       effector pro-inflammatory caspase (CASP1 and, possibly, CASP4 and
CC       CASP5) (PubMed:11786556, PubMed:15030775, PubMed:21880711).
CC       Homodecamer; inactive NLRP3 forms homodecameric double-ring cages that
CC       hide pyrin domains within NACHT-LRR rings to avoid premature activation
CC       (PubMed:35114687, PubMed:35254907). Interacts (via pyrin domain) with
CC       PYCARD/ASC (via pyrin domain); interaction is direct (PubMed:11786556,
CC       PubMed:34341353, PubMed:27432880, PubMed:35559676, PubMed:36142182,
CC       PubMed:36442502). Interacts (via LRR repeat domain) with NEK7 (via N-
CC       terminus); the interaction is required for the formation of the complex
CC       NLRP3:PYCARD, oligomerization of PYCARD/ASC and activation of CASP1
CC       (PubMed:31189953, PubMed:36442502). Interacts (via LRR repeat domain)
CC       with NR4A1/Nur77 (via N-terminus); the interaction is direct, requires
CC       activation of NR4A1 by its ligands NBRE-containing dsDNA and
CC       lipopolysaccharide, and stimulates the association of NLRP3 with NEK7
CC       for non-canonical NLRP3 inflammasome activation (By similarity).
CC       Interacts with CARD8; leading to inhibit formation of the NLRP3
CC       inflammasome (PubMed:24517500). Interacts with MEFV; this interaction
CC       targets NLRP3 to degradation by autophagy, hence preventing excessive
CC       IL1B- and IL18-mediated inflammation (PubMed:17431422,
CC       PubMed:26347139). Interacts with EIF2AK2/PKR; this interaction requires
CC       EIF2AK2 activity, is accompanied by EIF2AK2 autophosphorylation and
CC       promotes inflammasome assembly in response to specific stimuli
CC       (PubMed:22801494). Interacts with GBP5 (via DAPIN domain); this
CC       interaction promotes inflammasome assembly in response to microbial and
CC       soluble, but not crystalline, agents (PubMed:22461501). Interacts with
CC       PML (isoform PML-1) (via the leucine-rich repeat (LRR) domain); PML-
CC       mediated increase in NLRP3 inflammasome activation does not depend upon
CC       this interaction (PubMed:23430110). Interacts (via NACHT domain) with
CC       DHX33 (via DEAH box); NLRP3 activation in presence of cytosolic dsRNA
CC       is mediated by DHX33 (PubMed:23871209). Interacts (via NACHT and LRR
CC       domains) with ARRB2; this interaction is direct and inducible by
CC       polyunsaturated fatty acids (PUFAs) (PubMed:23809162). Interacts with
CC       PYDC5 (PubMed:24531343). Interacts (via NACHT domain) with DDX3X under
CC       both LPS-primed and inflammasome-activating conditions (By similarity).
CC       Interacts with IRF4 (via the LRR domain); this interaction is direct
CC       and is required for optimal IRF4 binding to IL4 promoter and efficient
CC       IL4 transactivation during differentiation of Th2 helper T-cells (By
CC       similarity). Interacts with MAVS; promoting localization to
CC       mitochondria and activation of the NLRP3 inflammasome
CC       (PubMed:23582325). Interacts with MARK4; promoting localization of
CC       NLRP3 to the microtubule organizing center (MTOC) (PubMed:28656979).
CC       Interacts with TRIM50; this interaction promotes also NLRP3
CC       oligomerization and subsequent inflammasome activation (By similarity).
CC       Interacts with IRGM; preventing NLRP3 inflammasome assembly and
CC       promoting NLRP3 degradation (PubMed:30612879). Interacts (via KFERQ-
CC       like motifs) with HSPA8/HSC70; promoting NLRP3 degradation by the
CC       chaperone-mediated autophagy pathway (PubMed:36586411).
CC       {ECO:0000250|UniProtKB:Q8R4B8, ECO:0000269|PubMed:11786556,
CC       ECO:0000269|PubMed:15030775, ECO:0000269|PubMed:17431422,
CC       ECO:0000269|PubMed:21880711, ECO:0000269|PubMed:22461501,
CC       ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:23430110,
CC       ECO:0000269|PubMed:23582325, ECO:0000269|PubMed:23809162,
CC       ECO:0000269|PubMed:23871209, ECO:0000269|PubMed:24517500,
CC       ECO:0000269|PubMed:24531343, ECO:0000269|PubMed:26347139,
CC       ECO:0000269|PubMed:27432880, ECO:0000269|PubMed:28656979,
CC       ECO:0000269|PubMed:30612879, ECO:0000269|PubMed:31189953,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35114687,
CC       ECO:0000269|PubMed:35254907, ECO:0000269|PubMed:35559676,
CC       ECO:0000269|PubMed:36142182, ECO:0000269|PubMed:36442502,
CC       ECO:0000269|PubMed:36586411}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS coronavirus-2/SARS-
CC       CoV-2 N protein; the interaction is direct and promotes the binding of
CC       NLRP3 with PYCARD/ASC and facilitates NLRP3 inflammasome assembly.
CC       {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with M.pneumoniae CARDS toxin,
CC       which ADP-ribosylates NLRP3. {ECO:0000269|PubMed:25538194}.
CC   -!- INTERACTION:
CC       Q96P20; P27797: CALR; NbExp=3; IntAct=EBI-6253230, EBI-1049597;
CC       Q96P20; P36957: DLST; NbExp=3; IntAct=EBI-6253230, EBI-351007;
CC       Q96P20; P19525: EIF2AK2; NbExp=6; IntAct=EBI-6253230, EBI-640775;
CC       Q96P20; Q7Z434: MAVS; NbExp=4; IntAct=EBI-6253230, EBI-995373;
CC       Q96P20; Q8TDX7: NEK7; NbExp=4; IntAct=EBI-6253230, EBI-1055945;
CC       Q96P20; Q96P20: NLRP3; NbExp=2; IntAct=EBI-6253230, EBI-6253230;
CC       Q96P20; Q9ULZ3: PYCARD; NbExp=25; IntAct=EBI-6253230, EBI-751215;
CC       Q96P20; Q80H93: 8b; Xeno; NbExp=7; IntAct=EBI-6253230, EBI-25492924;
CC       Q96P20; P0DTC9: N; Xeno; NbExp=18; IntAct=EBI-6253230, EBI-25475856;
CC       Q96P20; Q9ES74: Nek7; Xeno; NbExp=2; IntAct=EBI-6253230, EBI-16193749;
CC       Q96P20-1; Q8TDX7-1: NEK7; NbExp=6; IntAct=EBI-14029575, EBI-16193799;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:11786556,
CC       ECO:0000269|PubMed:14662828, ECO:0000269|PubMed:17164409}. Inflammasome
CC       {ECO:0000269|PubMed:11786556, ECO:0000269|PubMed:14662828,
CC       ECO:0000269|PubMed:17164409, ECO:0000269|PubMed:23871209,
CC       ECO:0000269|PubMed:25538194, ECO:0000269|PubMed:33231615}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center
CC       {ECO:0000269|PubMed:28656979}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:23229815, ECO:0000269|PubMed:30487600}. Endoplasmic
CC       reticulum {ECO:0000250|UniProtKB:Q8R4B8}. Mitochondrion
CC       {ECO:0000269|PubMed:21124315, ECO:0000269|PubMed:23582325}. Secreted
CC       {ECO:0000269|PubMed:24952504}. Nucleus {ECO:0000250|UniProtKB:Q8R4B8}.
CC       Note=In macrophages, under resting conditions, mainly located in the
CC       cytosol and on membranes of various organelles, such as endoplasmic
CC       reticulum, mitochondria and Golgi: forms an inactive double-ring cage
CC       that is primarily localized on membranes (By similarity). Upon
CC       activation, NLRP3 is transported to microtubule organizing center
CC       (MTOC), where it is unlocked by NEK7, leading to its relocalization to
CC       dispersed trans-Golgi network (dTGN) vesicle membranes for the
CC       formation of an active inflammasome complex (By similarity). Recruited
CC       to dTGN vesicle membranes by binding to phosphatidylinositol 4-
CC       phosphate (PtdIns4P) (PubMed:30487600). After the induction of
CC       pyroptosis, inflammasome specks are released into the extracellular
CC       space where they can further promote IL1B processing and where they can
CC       be engulfed by macrophages (PubMed:24952504). Phagocytosis induces
CC       lysosomal damage and inflammasome activation in the recipient cells
CC       (PubMed:24952504). In the Th2 subset of CD4(+) helper T-cells, mainly
CC       located in the nucleus (By similarity). Nuclear localization depends
CC       upon KPNA2 (By similarity). In the Th1 subset of CD4(+) helper T-cells,
CC       mainly cytoplasmic (By similarity). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000269|PubMed:24952504, ECO:0000269|PubMed:30487600}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=2;
CC         IsoId=Q96P20-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q96P20-2; Sequence=VSP_005520, VSP_005521;
CC       Name=3;
CC         IsoId=Q96P20-3; Sequence=VSP_005519;
CC       Name=4;
CC         IsoId=Q96P20-4; Sequence=VSP_005520;
CC       Name=5;
CC         IsoId=Q96P20-5; Sequence=VSP_005521;
CC       Name=6;
CC         IsoId=Q96P20-6; Sequence=VSP_053714;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in macrophages
CC       (PubMed:33231615, PubMed:34133077). Also expressed in dendritic cells,
CC       B- and T-cells (at protein level) (PubMed:11786556) (PubMed:17164409).
CC       Expressed in LPS-treated granulocytes, but not in resting cells (at
CC       protein level) (PubMed:17164409). Expression in monocytes is very weak
CC       (at protein level) (PubMed:17164409). Expressed in stratified non-
CC       keratinizing squamous epithelium, including oral, esophageal and
CC       ectocervical mucosa and in the Hassall's corpuscles in the thymus.
CC       Also, detected in the stratified epithelium covering the bladder and
CC       ureter (transitional mucosa) (at protein level) (PubMed:17164409).
CC       Expressed in lung epithelial cells (at protein level)
CC       (PubMed:23229815). Expressed in chondrocytes (PubMed:12032915).
CC       Expressed at low levels in resting osteoblasts (PubMed:17907925).
CC       {ECO:0000269|PubMed:11786556, ECO:0000269|PubMed:12032915,
CC       ECO:0000269|PubMed:17164409, ECO:0000269|PubMed:17907925,
CC       ECO:0000269|PubMed:23229815, ECO:0000269|PubMed:33231615,
CC       ECO:0000269|PubMed:34133077}.
CC   -!- INDUCTION: By activators of Toll-like receptors, such as lipoteichoic
CC       acid (LTA) (TLR2), polyinosine-polycytidylic acid (poly(I:C), a
CC       synthetic analog of dsRNA) (TLR3) and bacterial lipopolysaccharides
CC       (LPS) (TLR4), and by TNF (PubMed:14662828). Up-regulated in osteoblasts
CC       after exposure to invasive, but not invasion-defective, strains of
CC       Salmonella typhimurium (at protein level) (PubMed:17907925). In
CC       macrophages, up-regulated by endocannabinoid anandamide/AEA
CC       (PubMed:23955712). {ECO:0000269|PubMed:14662828,
CC       ECO:0000269|PubMed:17907925, ECO:0000269|PubMed:23955712}.
CC   -!- INDUCTION: (Microbial infection) In COVID-19 patient derived
CC       macrophages, expression is induced by SARS-CoV-2 spike protein,
CC       probably via TLR2 (at protein level). {ECO:0000269|PubMed:34133077}.
CC   -!- DOMAIN: The pyrin domain (also called DAPIN domain or PYD) is involved
CC       in PYCARD/ASC-binding. {ECO:0000269|PubMed:24630722}.
CC   -!- DOMAIN: The FISNA domain is a critical mediator of NLRP3 conformational
CC       during NLRP3 activation (PubMed:34524838, PubMed:36442502). It becomes
CC       ordered in its key regions during activation to stabilize the active
CC       NACHT conformation and mediate most interactions in the NLRP3 disk
CC       (PubMed:36442502). {ECO:0000269|PubMed:34524838,
CC       ECO:0000269|PubMed:36442502}.
CC   -!- DOMAIN: The LRR domain mediates the interaction with IRF4, PML, NEK7
CC       and NR4A1/Nur77. {ECO:0000269|PubMed:23430110}.
CC   -!- DOMAIN: The KFERQ-like motifs mediate binding to HSPA8/HSC70 following
CC       NLRP3 paylmitoylation by ZDHHC12. {ECO:0000269|PubMed:36586411}.
CC   -!- PTM: Phosphorylation at Ser-198 by MAPK8/JNK1 increases inflammasome
CC       activation by promoting deubiquitination by BRCC3 and NLRP3
CC       homooligomerization (PubMed:28943315). Phosphorylation at Ser-806 by
CC       CSNK1A1 prevents inflammasome activation by preventing NEK7 recruitment
CC       (PubMed:34615873). Phosphorylation at Ser-5 in the pyrin domain
CC       inhibits homomultimerization of NLRP3 and activation of the NLRP3
CC       inflammasome: dephosphorylation by protein phosphatase 2A (PP2A)
CC       promotes assembly of the NLRP3 inflammasome (PubMed:28465465).
CC       Phosphorylation at Ser-295 by PKD/PRKD1 promotes NLRP3 inflammasome
CC       assembly (By similarity). Phosphorylation by ERK1/MAPK3 promotes NLRP3
CC       inflammasome assembly (PubMed:24623131). Phosphorylation by BTK (at
CC       Tyr-136, Tyr-140, Tyr-143 and Tyr-168) in the region that mediates
CC       binding to phosphatidylinositol phosphate, promotes relocalization of
CC       NLRP3 and assembly of the NLRP3 inflammasome (PubMed:34554188).
CC       Phosphorylation at Tyr-861 inhibits NLRP3 inflammasome assembly:
CC       dephosphorylation by PTPN22 promotes inflammasome activation
CC       (PubMed:27043286). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000269|PubMed:24623131, ECO:0000269|PubMed:27043286,
CC       ECO:0000269|PubMed:28465465, ECO:0000269|PubMed:28943315,
CC       ECO:0000269|PubMed:34554188, ECO:0000269|PubMed:34615873}.
CC   -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitination (PubMed:22948162, PubMed:27929086). Ubiquitination
CC       does not lead to degradation, but inhibits inflammasome activation (By
CC       similarity). Deubiquitination is catalyzed by BRCC3 and associated with
CC       NLRP3 activation and inflammasome assembly (By similarity). This
CC       process can be induced by the activation of Toll-like receptors (by
CC       LPS), through a non-transcriptional pathway dependent on the
CC       mitochondrial production of reactive oxygen species, and by ATP (By
CC       similarity). Ubiquitinated by TRIM31 via 'Lys-48'-linked
CC       ubiquitination, leading to its degradation by the proteasome
CC       (PubMed:27929086). Ubiquitinated at Lys-689 by the SCF(FBXL2) complex,
CC       leading to its degradation by the proteasome (PubMed:26037928).
CC       Ubiquitinated by TRIM35 via 'lys-48' and 'Lys-63'-linked ubiquitination
CC       leading to inhibition of NLRP3 inflammasome activation
CC       (PubMed:34512673). {ECO:0000250|UniProtKB:Q8R4B8,
CC       ECO:0000269|PubMed:22948162, ECO:0000269|PubMed:26037928,
CC       ECO:0000269|PubMed:27929086, ECO:0000269|PubMed:34512673}.
CC   -!- PTM: Palmitoylation by ZDHHC12 inhibits the NLRP3 inflammasome by
CC       promoting NLRP3 degradation by the chaperone-mediated autophagy pathway
CC       (PubMed:36586411). Following palmitoylation, HSPA8/HSC70 recognizes and
CC       binds the KFERQ-like motifs on NLRP3 and promotes NLRP3 recruitment to
CC       lysosomes, where it is degraded via the chaperone-mediated autophagy
CC       pathway in a LAMP2-dependent process (PubMed:36586411).
CC       {ECO:0000269|PubMed:36586411}.
CC   -!- PTM: Degraded via selective autophagy following interaction with IRGM
CC       (PubMed:30612879). IRGM promotes NLRP3 recruitment to autophagosome
CC       membranes, promoting its SQSTM1/p62-dependent autophagy-dependent
CC       degradation (PubMed:30612879). {ECO:0000269|PubMed:30612879}.
CC   -!- PTM: The disulfide bond in the pyrin domain might play a role in
CC       reactive oxygen species-mediated activation.
CC       {ECO:0000305|PubMed:21880711}.
CC   -!- PTM: (Microbial infection) ADP-ribosylated by M.pneumoniae CARDS toxin
CC       in vitro. {ECO:0000269|PubMed:25538194}.
CC   -!- DISEASE: Familial cold autoinflammatory syndrome 1 (FCAS1)
CC       [MIM:120100]: A rare autosomal dominant systemic inflammatory disease
CC       characterized by recurrent episodes of maculopapular rash associated
CC       with arthralgias, myalgias, fever and chills, swelling of the
CC       extremities, and conjunctivitis after generalized exposure to cold.
CC       Rarely, some patients may also develop late-onset renal amyloidosis.
CC       {ECO:0000269|PubMed:11687797, ECO:0000269|PubMed:11992256,
CC       ECO:0000269|PubMed:12355493, ECO:0000269|PubMed:12522564,
CC       ECO:0000269|PubMed:15593220, ECO:0000269|PubMed:17284928,
CC       ECO:0000269|PubMed:24952504}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Muckle-Wells syndrome (MWS) [MIM:191900]: A hereditary
CC       periodic fever syndrome characterized by fever, chronic recurrent
CC       urticaria, arthralgias, progressive sensorineural deafness, and
CC       reactive renal amyloidosis. The disease may be severe if generalized
CC       reactive amyloidosis occurs. {ECO:0000269|PubMed:11687797,
CC       ECO:0000269|PubMed:11992256, ECO:0000269|PubMed:12355493,
CC       ECO:0000269|PubMed:15593220, ECO:0000269|PubMed:24952504}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Chronic infantile neurologic cutaneous and articular syndrome
CC       (CINCA) [MIM:607115]: Rare congenital inflammatory disorder
CC       characterized by a triad of neonatal onset of cutaneous symptoms,
CC       chronic meningitis, and joint manifestations with recurrent fever and
CC       inflammation. {ECO:0000269|PubMed:12032915,
CC       ECO:0000269|PubMed:12483741, ECO:0000269|PubMed:14630794,
CC       ECO:0000269|PubMed:15231984, ECO:0000269|PubMed:15334500,
CC       ECO:0000269|PubMed:15593220, ECO:0000269|PubMed:24952504,
CC       ECO:0000269|PubMed:31086329}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Keratoendothelitis fugax hereditaria (KEFH) [MIM:148200]: An
CC       autosomal dominant corneal disease that periodically, and fleetingly,
CC       affects the corneal endothelium, stroma, and vision, eventually leading
CC       to central corneal stromal opacities in some patients. The disease is
CC       characterized by unilateral attacks of ocular pain, pericorneal
CC       injection, and photophobia. The acute symptoms vanish in 1-2 days but
CC       vision remains blurry for several weeks. The attacks start at the age
CC       of 3-12 years and can affect either eye. They generally decrease in
CC       frequency and get milder with age. {ECO:0000269|PubMed:29366613,
CC       ECO:0000269|PubMed:35559676}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Deafness, autosomal dominant, 34, with or without inflammation
CC       (DFNA34) [MIM:617772]: A form of sensorineural hearing loss.
CC       Sensorineural deafness results from damage to the neural receptors of
CC       the inner ear, the nerve pathways to the brain, or the area of the
CC       brain that receives sound information. DFNA34 is a postlingual, slowly
CC       progressive form with variable severity and variable additional
CC       features. Some DFNA34 patients have autoinflammatory manifestations.
CC       {ECO:0000269|PubMed:28847925}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC39910.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAL12497.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAL12498.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAL33908.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAL65136.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAD92128.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG37494.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditary
CC       autoinflammatory disorders mutations;
CC       URL="https://infevers.umai-montpellier.fr/web/search.php?n=4";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF410477; AAL33908.1; ALT_INIT; mRNA.
DR   EMBL; AF427617; AAL33911.1; -; mRNA.
DR   EMBL; AY051117; AAL12497.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AY051112; AAL12497.1; JOINED; Genomic_DNA.
DR   EMBL; AY051113; AAL12497.1; JOINED; Genomic_DNA.
DR   EMBL; AY051114; AAL12497.1; JOINED; Genomic_DNA.
DR   EMBL; AY051115; AAL12497.1; JOINED; Genomic_DNA.
DR   EMBL; AY051116; AAL12497.1; JOINED; Genomic_DNA.
DR   EMBL; AY056059; AAL12497.1; JOINED; Genomic_DNA.
DR   EMBL; AY056060; AAL12497.1; JOINED; Genomic_DNA.
DR   EMBL; AY051117; AAL12498.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AY051112; AAL12498.1; JOINED; Genomic_DNA.
DR   EMBL; AY051113; AAL12498.1; JOINED; Genomic_DNA.
DR   EMBL; AY051114; AAL12498.1; JOINED; Genomic_DNA.
DR   EMBL; AY051115; AAL12498.1; JOINED; Genomic_DNA.
DR   EMBL; AY051116; AAL12498.1; JOINED; Genomic_DNA.
DR   EMBL; AF468522; AAL78632.1; -; mRNA.
DR   EMBL; AF420469; AAL65136.1; ALT_INIT; mRNA.
DR   EMBL; AY092033; AAM14669.1; -; mRNA.
DR   EMBL; AF418985; AAL14640.2; -; mRNA.
DR   EMBL; AK314998; BAG37494.1; ALT_INIT; mRNA.
DR   EMBL; AB208891; BAD92128.1; ALT_INIT; mRNA.
DR   EMBL; AC104335; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL606804; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471148; EAW77184.1; -; Genomic_DNA.
DR   EMBL; CH471148; EAW77186.1; -; Genomic_DNA.
DR   EMBL; BC117211; AAI17212.1; -; mRNA.
DR   EMBL; BC143359; AAI43360.1; -; mRNA.
DR   EMBL; BC143362; AAI43363.1; -; mRNA.
DR   EMBL; BC143363; AAI43364.1; -; mRNA.
DR   EMBL; AY422168; AAQ98889.1; -; mRNA.
DR   EMBL; AF054176; AAC39910.1; ALT_FRAME; mRNA.
DR   RefSeq; NP_001073289.1; NM_001079821.2.
DR   RefSeq; NP_001120933.1; NM_001127461.2.
DR   RefSeq; NP_001120934.1; NM_001127462.2.
DR   RefSeq; NP_001230062.1; NM_001243133.1.
DR   RefSeq; NP_004886.3; NM_004895.4. [Q96P20-1]
DR   RefSeq; NP_899632.1; NM_183395.2.
DR   RefSeq; XP_011542350.1; XM_011544048.2.
DR   RefSeq; XP_016855670.1; XM_017000181.1. [Q96P20-1]
DR   RefSeq; XP_016855671.1; XM_017000182.1. [Q96P20-1]
DR   RefSeq; XP_016855672.1; XM_017000183.1.
DR   RefSeq; XP_016855673.1; XM_017000184.1.
DR   PDB; 2NAQ; NMR; -; A=3-93.
DR   PDB; 3QF2; X-ray; 1.70 A; A/B=3-112.
DR   PDB; 6NPY; EM; 3.80 A; A=3-1036.
DR   PDB; 7ALV; X-ray; 2.83 A; A=131-679.
DR   PDB; 7PZC; EM; 3.90 A; A/B/C/D/E/F/G/H/I/J=1-1036.
DR   PDB; 7PZD; EM; 3.60 A; G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=3-110.
DR   PDB; 7VTP; EM; 3.23 A; A/B/C/D/E/F=130-1036.
DR   PDB; 7ZGU; EM; 3.40 A; A/B/C/D/E/F=126-1036.
DR   PDB; 8EJ4; EM; 3.40 A; A/B/C/D/E/F/G/H/I=133-1004.
DR   PDB; 8ERT; EM; 3.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W=1-95.
DR   PDB; 8ETR; EM; 3.50 A; A=134-676.
DR   PDBsum; 2NAQ; -.
DR   PDBsum; 3QF2; -.
DR   PDBsum; 6NPY; -.
DR   PDBsum; 7ALV; -.
DR   PDBsum; 7PZC; -.
DR   PDBsum; 7PZD; -.
DR   PDBsum; 7VTP; -.
DR   PDBsum; 7ZGU; -.
DR   PDBsum; 8EJ4; -.
DR   PDBsum; 8ERT; -.
DR   PDBsum; 8ETR; -.
DR   AlphaFoldDB; Q96P20; -.
DR   SMR; Q96P20; -.
DR   BioGRID; 125319; 105.
DR   ComplexPortal; CPX-4141; NLRP3 inflammasome.
DR   CORUM; Q96P20; -.
DR   DIP; DIP-41153N; -.
DR   IntAct; Q96P20; 50.
DR   MINT; Q96P20; -.
DR   STRING; 9606.ENSP00000337383; -.
DR   BindingDB; Q96P20; -.
DR   ChEMBL; CHEMBL1741208; -.
DR   GuidetoPHARMACOLOGY; 1770; -.
DR   iPTMnet; Q96P20; -.
DR   PhosphoSitePlus; Q96P20; -.
DR   BioMuta; NLRP3; -.
DR   DMDM; 262527566; -.
DR   EPD; Q96P20; -.
DR   MassIVE; Q96P20; -.
DR   MaxQB; Q96P20; -.
DR   PaxDb; 9606-ENSP00000337383; -.
DR   PeptideAtlas; Q96P20; -.
DR   ProteomicsDB; 77599; -. [Q96P20-1]
DR   ProteomicsDB; 77600; -. [Q96P20-2]
DR   ProteomicsDB; 77601; -. [Q96P20-3]
DR   ProteomicsDB; 77602; -. [Q96P20-4]
DR   ProteomicsDB; 77603; -. [Q96P20-5]
DR   Antibodypedia; 624; 854 antibodies from 46 providers.
DR   DNASU; 114548; -.
DR   GeneID; 114548; -.
DR   KEGG; hsa:114548; -.
DR   UCSC; uc001icr.4; human. [Q96P20-1]
DR   AGR; HGNC:16400; -.
DR   CTD; 114548; -.
DR   DisGeNET; 114548; -.
DR   GeneCards; NLRP3; -.
DR   HGNC; HGNC:16400; NLRP3.
DR   MalaCards; NLRP3; -.
DR   MIM; 120100; phenotype.
DR   MIM; 148200; phenotype.
DR   MIM; 191900; phenotype.
DR   MIM; 606416; gene.
DR   MIM; 607115; phenotype.
DR   MIM; 617772; phenotype.
DR   neXtProt; NX_Q96P20; -.
DR   Orphanet; 1451; CINCA syndrome.
DR   Orphanet; 47045; Familial cold urticaria.
DR   Orphanet; 647815; Keratoendotheliitis fugax hereditaria.
DR   Orphanet; 575; Muckle-Wells syndrome.
DR   PharmGKB; PA26512; -.
DR   VEuPathDB; HostDB:ENSG00000162711; -.
DR   eggNOG; ENOG502SBIG; Eukaryota.
DR   HOGENOM; CLU_002274_2_0_1; -.
DR   InParanoid; Q96P20; -.
DR   OrthoDB; 55870at2759; -.
DR   PhylomeDB; Q96P20; -.
DR   TreeFam; TF340267; -.
DR   PathwayCommons; Q96P20; -.
DR   Reactome; R-HSA-5689901; Metalloprotease DUBs.
DR   Reactome; R-HSA-844456; The NLRP3 inflammasome.
DR   Reactome; R-HSA-9660826; Purinergic signaling in leishmaniasis infection.
DR   Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9707564; Cytoprotection by HMOX1.
DR   SignaLink; Q96P20; -.
DR   SIGNOR; Q96P20; -.
DR   BioGRID-ORCS; 114548; 5 hits in 1142 CRISPR screens.
DR   ChiTaRS; NLRP3; human.
DR   GeneWiki; NALP3; -.
DR   GenomeRNAi; 114548; -.
DR   Pharos; Q96P20; Tchem.
DR   PRO; PR:Q96P20; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q96P20; Protein.
DR   Bgee; ENSG00000162711; Expressed in monocyte and 105 other tissues.
DR   ExpressionAtlas; Q96P20; baseline and differential.
DR   Genevisible; Q96P20; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProt.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0031021; C:interphase microtubule organizing center; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0072559; C:NLRP3 inflammasome complex; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0043531; F:ADP binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0140608; F:cysteine-type endopeptidase activator activity; IDA:UniProt.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProt.
DR   GO; GO:0042834; F:peptidoglycan binding; TAS:HGNC-UCL.
DR   GO; GO:1901981; F:phosphatidylinositol phosphate binding; IDA:UniProtKB.
DR   GO; GO:0070273; F:phosphatidylinositol-4-phosphate binding; IDA:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0035591; F:signaling adaptor activity; IDA:UniProtKB.
DR   GO; GO:0140299; F:small molecule sensor activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; NAS:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB.
DR   GO; GO:0006952; P:defense response; TAS:HGNC-UCL.
DR   GO; GO:0009595; P:detection of biotic stimulus; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0002674; P:negative regulation of acute inflammatory response; IMP:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:BHF-UCL.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; IMP:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:HGNC-UCL.
DR   GO; GO:1901223; P:negative regulation of non-canonical NF-kappaB signal transduction; IDA:HGNC-UCL.
DR   GO; GO:0044546; P:NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0007231; P:osmosensory signaling pathway; NAS:ComplexPortal.
DR   GO; GO:0002221; P:pattern recognition receptor signaling pathway; NAS:ComplexPortal.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:HGNC-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IDA:UniProtKB.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IDA:UniProtKB.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; IPI:UniProtKB.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0002830; P:positive regulation of type 2 immune response; ISS:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0051604; P:protein maturation; IDA:UniProt.
DR   GO; GO:0070269; P:pyroptosis; NAS:ComplexPortal.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   CDD; cd00116; LRR_RI; 1.
DR   CDD; cd08320; Pyrin_NALPs; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   InterPro; IPR004020; DAPIN.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR029495; NACHT-assoc.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR041267; NLRP_HD2.
DR   InterPro; IPR041075; NOD2_WH.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR45690; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 12; 1.
DR   PANTHER; PTHR45690:SF19; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 3; 1.
DR   Pfam; PF14484; FISNA; 1.
DR   Pfam; PF13516; LRR_6; 5.
DR   Pfam; PF05729; NACHT; 1.
DR   Pfam; PF17776; NLRC4_HD2; 1.
DR   Pfam; PF17779; NOD2_WH; 1.
DR   Pfam; PF02758; PYRIN; 1.
DR   SMART; SM01288; FISNA; 1.
DR   SMART; SM00368; LRR_RI; 9.
DR   SMART; SM01289; PYRIN; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF52047; RNI-like; 1.
DR   PROSITE; PS50824; DAPIN; 1.
DR   PROSITE; PS50837; NACHT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; ADP-ribosylation; Alternative splicing;
KW   Amyloidosis; ATP-binding; Cytoplasm; Cytoskeleton; Deafness;
KW   Disease variant; Disulfide bond; Endoplasmic reticulum; Golgi apparatus;
KW   Hydrolase; Immunity; Inflammasome; Inflammatory response; Innate immunity;
KW   Isopeptide bond; Leucine-rich repeat; Lipoprotein; Membrane; Mitochondrion;
KW   Non-syndromic deafness; Nucleotide-binding; Nucleus; Palmitate;
KW   Phosphoprotein; Reference proteome; Repeat; Secreted; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1036
FT                   /note="NACHT, LRR and PYD domains-containing protein 3"
FT                   /id="PRO_0000080886"
FT   DOMAIN          1..93
FT                   /note="Pyrin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00061"
FT   DOMAIN          140..210
FT                   /note="FISNA"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          220..536
FT                   /note="NACHT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   REPEAT          742..762
FT                   /note="LRR 1"
FT   REPEAT          771..792
FT                   /note="LRR 2"
FT   REPEAT          799..819
FT                   /note="LRR 3"
FT   REPEAT          828..849
FT                   /note="LRR 4"
FT   REPEAT          856..876
FT                   /note="LRR 5"
FT   REPEAT          885..906
FT                   /note="LRR 6"
FT   REPEAT          913..933
FT                   /note="LRR 7"
FT   REPEAT          942..963
FT                   /note="LRR 8"
FT   REPEAT          970..991
FT                   /note="LRR 9"
FT   REGION          131..134
FT                   /note="Required for binding to phosphatidylinositol 4-
FT                   phosphate (PtdIns4P)"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   MOTIF           355..359
FT                   /note="KFERQ-like motif 1"
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MOTIF           603..607
FT                   /note="KFERQ-like motif 2"
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MOTIF           798..802
FT                   /note="KFERQ-like motif 3"
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MOTIF           991..995
FT                   /note="KFERQ-like motif 4"
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   BINDING         169
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|PubMed:35254907,
FT                   ECO:0000305|PubMed:36142182, ECO:0000305|PubMed:36442502,
FT                   ECO:0007744|PDB:7VTP, ECO:0007744|PDB:7ZGU,
FT                   ECO:0007744|PDB:8EJ4"
FT   BINDING         226..234
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136,
FT                   ECO:0000269|PubMed:17483456, ECO:0000305|PubMed:34687713,
FT                   ECO:0000305|PubMed:35114687, ECO:0000305|PubMed:35254907,
FT                   ECO:0000305|PubMed:36142182, ECO:0000305|PubMed:36442502,
FT                   ECO:0007744|PDB:7ALV, ECO:0007744|PDB:7PZC,
FT                   ECO:0007744|PDB:7VTP, ECO:0007744|PDB:7ZGU,
FT                   ECO:0007744|PDB:8EJ4"
FT   BINDING         522
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|PubMed:34687713,
FT                   ECO:0000305|PubMed:35114687, ECO:0000305|PubMed:35254907,
FT                   ECO:0000305|PubMed:36142182, ECO:0007744|PDB:7ALV,
FT                   ECO:0007744|PDB:7PZC, ECO:0007744|PDB:7VTP,
FT                   ECO:0007744|PDB:7ZGU"
FT   MOD_RES         5
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28465465"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:28943315"
FT   MOD_RES         136
FT                   /note="Phosphotyrosine; by BTK"
FT                   /evidence="ECO:0000269|PubMed:34554188"
FT   MOD_RES         140
FT                   /note="Phosphotyrosine; by BTK"
FT                   /evidence="ECO:0000269|PubMed:34554188"
FT   MOD_RES         143
FT                   /note="Phosphotyrosine; by BTK"
FT                   /evidence="ECO:0000269|PubMed:34554188"
FT   MOD_RES         161
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   MOD_RES         163
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28943315"
FT   MOD_RES         168
FT                   /note="Phosphotyrosine; by BTK"
FT                   /evidence="ECO:0000269|PubMed:34554188"
FT   MOD_RES         198
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28943315"
FT   MOD_RES         198
FT                   /note="Phosphoserine; by MAPK8"
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MOD_RES         201
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MOD_RES         295
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R4B8"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28943315"
FT   MOD_RES         728
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28943315"
FT   MOD_RES         735
FT                   /note="Phosphoserine; by CSNK1A1"
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   MOD_RES         806
FT                   /note="Phosphoserine; by CSNK1A1"
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   MOD_RES         861
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:27043286"
FT   MOD_RES         975
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28943315"
FT   MOD_RES         1035
FT                   /note="Phosphoserine; by CSNK1A1"
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   LIPID           844
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   DISULFID        8..108
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000269|PubMed:21880711"
FT   CROSSLNK        689
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:26037928"
FT   CROSSLNK        878
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   CROSSLNK        927
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   CROSSLNK        973
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   VAR_SEQ         720..1036
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12355493"
FT                   /id="VSP_005519"
FT   VAR_SEQ         721..777
FT                   /note="Missing (in isoform 1 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11042152,
FT                   ECO:0000303|PubMed:11687797, ECO:0000303|PubMed:12355493,
FT                   ECO:0000303|PubMed:14662828, ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_005520"
FT   VAR_SEQ         776..796
FT                   /note="WLGRCGLSHECCFDISLVLSS -> C (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_053714"
FT   VAR_SEQ         836..892
FT                   /note="Missing (in isoform 1 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11042152,
FT                   ECO:0000303|PubMed:11687797, ECO:0000303|PubMed:12355493,
FT                   ECO:0000303|PubMed:14662828, ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|Ref.5"
FT                   /id="VSP_005521"
FT   VARIANT         21
FT                   /note="D -> H (in KEFH; does not affect ability to
FT                   homooligomerize into ordered polymers; dbSNP:rs200154873)"
FT                   /evidence="ECO:0000269|PubMed:29366613,
FT                   ECO:0000269|PubMed:35559676"
FT                   /id="VAR_080490"
FT   VARIANT         174
FT                   /note="I -> T (in CINCA; dbSNP:rs180177449)"
FT                   /evidence="ECO:0000269|PubMed:15231984"
FT                   /id="VAR_043679"
FT   VARIANT         200
FT                   /note="V -> M (in FCAS1 and MWS; dbSNP:rs121908147)"
FT                   /evidence="ECO:0000269|PubMed:11687797,
FT                   ECO:0000269|PubMed:11992256, ECO:0000269|PubMed:12355493,
FT                   ECO:0000269|PubMed:15593220"
FT                   /id="VAR_013227"
FT   VARIANT         262
FT                   /note="R -> L (in CINCA; dbSNP:rs180177442)"
FT                   /evidence="ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043680"
FT   VARIANT         262
FT                   /note="R -> P (in CINCA; dbSNP:rs180177442)"
FT                   /evidence="ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043681"
FT   VARIANT         262
FT                   /note="R -> W (in FCAS1 and MWS; spontaneous polymerization
FT                   into inflammasome speck; dbSNP:rs121908150)"
FT                   /evidence="ECO:0000269|PubMed:11992256,
FT                   ECO:0000269|PubMed:12355493, ECO:0000269|PubMed:24952504"
FT                   /id="VAR_014104"
FT   VARIANT         266
FT                   /note="L -> H (in CINCA; dbSNP:rs180177436)"
FT                   /evidence="ECO:0000269|PubMed:12483741"
FT                   /id="VAR_043682"
FT   VARIANT         305
FT                   /note="D -> G (in CINCA; dbSNP:rs180177447)"
FT                   /evidence="ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043683"
FT   VARIANT         305
FT                   /note="D -> N (in CINCA and MWS; spontaneous polymerization
FT                   into inflammasome speck; dbSNP:rs121908153)"
FT                   /evidence="ECO:0000269|PubMed:11992256,
FT                   ECO:0000269|PubMed:12032915, ECO:0000269|PubMed:12483741,
FT                   ECO:0000269|PubMed:14630794, ECO:0000269|PubMed:15593220,
FT                   ECO:0000269|PubMed:24952504, ECO:0000269|PubMed:31086329"
FT                   /id="VAR_014105"
FT   VARIANT         307
FT                   /note="L -> P (in FCAS1 and MWS; dbSNP:rs180177431)"
FT                   /evidence="ECO:0000269|PubMed:12355493,
FT                   ECO:0000269|PubMed:15593220"
FT                   /id="VAR_014124"
FT   VARIANT         308
FT                   /note="Q -> K (in CINCA; dbSNP:rs180177432)"
FT                   /evidence="ECO:0000269|PubMed:12032915"
FT                   /id="VAR_043684"
FT   VARIANT         311
FT                   /note="F -> S (in CINCA; dbSNP:rs121908154)"
FT                   /evidence="ECO:0000269|PubMed:12032915,
FT                   ECO:0000269|PubMed:14630794"
FT                   /id="VAR_014106"
FT   VARIANT         350
FT                   /note="T -> M (in MWS and CINCA; spontaneous polymerization
FT                   into inflammasome speck; dbSNP:rs151344629)"
FT                   /evidence="ECO:0000269|PubMed:11992256,
FT                   ECO:0000269|PubMed:14630794, ECO:0000269|PubMed:15593220,
FT                   ECO:0000269|PubMed:24952504"
FT                   /id="VAR_014366"
FT   VARIANT         354
FT                   /note="A -> V (in MWS; dbSNP:rs121908149)"
FT                   /evidence="ECO:0000269|PubMed:11687797"
FT                   /id="VAR_013228"
FT   VARIANT         355
FT                   /note="L -> P (in FCAS1; dbSNP:rs28937896)"
FT                   /evidence="ECO:0000269|PubMed:12522564"
FT                   /id="VAR_043685"
FT   VARIANT         356
FT                   /note="E -> D (in CINCA; dbSNP:rs180177444)"
FT                   /evidence="ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043686"
FT   VARIANT         360
FT                   /note="H -> R (in CINCA; dbSNP:rs180177434)"
FT                   /evidence="ECO:0000269|PubMed:12032915"
FT                   /id="VAR_014367"
FT   VARIANT         407
FT                   /note="T -> P (in CINCA; dbSNP:rs180177445)"
FT                   /evidence="ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043687"
FT   VARIANT         438
FT                   /note="T -> I (in CINCA; dbSNP:rs180177433)"
FT                   /evidence="ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043688"
FT   VARIANT         438
FT                   /note="T -> N (in CINCA; dbSNP:rs180177433)"
FT                   /evidence="ECO:0000269|PubMed:12032915"
FT                   /id="VAR_014368"
FT   VARIANT         441
FT                   /note="A -> T (in MWS; dbSNP:rs180177430)"
FT                   /evidence="ECO:0000269|PubMed:11992256"
FT                   /id="VAR_014369"
FT   VARIANT         441
FT                   /note="A -> V (in FCAS1; dbSNP:rs121908146)"
FT                   /evidence="ECO:0000269|PubMed:11687797"
FT                   /id="VAR_013229"
FT   VARIANT         490
FT                   /note="R -> K (in FCAS1; dbSNP:rs145268073)"
FT                   /evidence="ECO:0000269|PubMed:15593220"
FT                   /id="VAR_043689"
FT   VARIANT         525
FT                   /note="F -> C (in FCAS1; dbSNP:rs180177478)"
FT                   /evidence="ECO:0000269|PubMed:17284928"
FT                   /id="VAR_031853"
FT   VARIANT         525
FT                   /note="F -> L (in CINCA; dbSNP:rs180177439)"
FT                   /evidence="ECO:0000269|PubMed:12483741"
FT                   /id="VAR_043690"
FT   VARIANT         571
FT                   /note="G -> R (in MWS; dbSNP:rs121908151)"
FT                   /evidence="ECO:0000269|PubMed:11992256"
FT                   /id="VAR_014107"
FT   VARIANT         572
FT                   /note="Y -> C (in CINCA; dbSNP:rs180177438)"
FT                   /evidence="ECO:0000269|PubMed:12483741,
FT                   ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043691"
FT   VARIANT         575
FT                   /note="F -> S (in CINCA; dbSNP:rs121908152)"
FT                   /evidence="ECO:0000269|PubMed:12032915"
FT                   /id="VAR_014108"
FT   VARIANT         629
FT                   /note="E -> G (in FCAS1; dbSNP:rs121908148)"
FT                   /evidence="ECO:0000269|PubMed:11687797"
FT                   /id="VAR_013230"
FT   VARIANT         634
FT                   /note="L -> F (in CINCA; dbSNP:rs180177446)"
FT                   /evidence="ECO:0000269|PubMed:14630794"
FT                   /id="VAR_043692"
FT   VARIANT         664
FT                   /note="M -> T (in CINCA; dbSNP:rs180177435)"
FT                   /evidence="ECO:0000269|PubMed:12032915"
FT                   /id="VAR_014370"
FT   VARIANT         705
FT                   /note="Q -> K (in dbSNP:rs35829419)"
FT                   /evidence="ECO:0000269|PubMed:12522564"
FT                   /id="VAR_043693"
FT   VARIANT         861
FT                   /note="Y -> C (in CINCA; dbSNP:rs180177452)"
FT                   /evidence="ECO:0000269|PubMed:15334500"
FT                   /id="VAR_023551"
FT   VARIANT         920
FT                   /note="R -> Q (in DFNA34; unknown pathological
FT                   significance; increases inflammatory response;
FT                   dbSNP:rs1553293095)"
FT                   /evidence="ECO:0000269|PubMed:28847925"
FT                   /id="VAR_081008"
FT   MUTAGEN         2..7
FT                   /note="Missing: Strongly decreased interaction with MAVS
FT                   and localization to mitochondria."
FT                   /evidence="ECO:0000269|PubMed:23582325"
FT   MUTAGEN         5
FT                   /note="S->A: Decreased phosphorylation; increased
FT                   activation of the NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:28465465"
FT   MUTAGEN         5
FT                   /note="S->D,E: Mimics phosphorylation state; decreased
FT                   activation of the NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:28465465"
FT   MUTAGEN         7..12
FT                   /note="RCKLAR->ACALAA: Abolished formation of the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:28465465"
FT   MUTAGEN         7
FT                   /note="R->E: Impaired ability to homooligomerize into
FT                   ordered polymers."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         15
FT                   /note="E->R: Impaired ability to homooligomerize into
FT                   ordered polymers. Complete loss of PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:24630722,
FT                   ECO:0000269|PubMed:35559676"
FT   MUTAGEN         22..23
FT                   /note="LK->PA: Loss of PYCARD/ASC-binding. No effect on
FT                   GBP5-binding."
FT                   /evidence="ECO:0000269|PubMed:22461501"
FT   MUTAGEN         23..24
FT                   /note="KK->EE: Impaired ability to homooligomerize into
FT                   ordered polymers. Complete loss of PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         23
FT                   /note="K->E: Complete loss of PYCARD/ASC filament
FT                   nucleation; when associated with E-24."
FT                   /evidence="ECO:0000269|PubMed:24630722"
FT   MUTAGEN         24
FT                   /note="K->E: Complete loss of PYCARD/ASC filament
FT                   nucleation; when associated with E-23."
FT                   /evidence="ECO:0000269|PubMed:24630722"
FT   MUTAGEN         27
FT                   /note="M->E: Impaired ability to homooligomerize into
FT                   ordered polymers. Complete loss of PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:24630722,
FT                   ECO:0000269|PubMed:35559676"
FT   MUTAGEN         31
FT                   /note="D->V: Impaired ability to homooligomerize into
FT                   ordered polymers. Decreased PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         43
FT                   /note="R->E: Impaired ability to homooligomerize into
FT                   ordered polymers."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         43
FT                   /note="R->W: Complete loss of PYCARD/ASC filament
FT                   nucleation. Decreased PYCARD/ASC filament nucleation."
FT                   /evidence="ECO:0000269|PubMed:24630722"
FT   MUTAGEN         51
FT                   /note="H->R: Does not affect ability to homooligomerize
FT                   into ordered polymers."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         52
FT                   /note="V->G: Decreased interaction with MAPK4."
FT                   /evidence="ECO:0000269|PubMed:28656979"
FT   MUTAGEN         64
FT                   /note="E->R: Complete loss of PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:24630722"
FT   MUTAGEN         68
FT                   /note="W->A: Does not affect ubiquitination by the
FT                   SCF(FBXL2) complex."
FT                   /evidence="ECO:0000269|PubMed:26037928"
FT   MUTAGEN         73
FT                   /note="W->A: Decreased ubiquitination by the SCF(FBXL2)
FT                   complex."
FT                   /evidence="ECO:0000269|PubMed:26037928"
FT   MUTAGEN         77
FT                   /note="A->V: Induces the formation of short but ordered
FT                   homopolymers."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         80
FT                   /note="R->E: Impaired ability to homooligomerize into
FT                   ordered polymers. Decreased PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         81
FT                   /note="R->E: Impaired ability to homooligomerize into
FT                   ordered polymers. Decreased PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:35559676"
FT   MUTAGEN         82
FT                   /note="D->R: Complete loss of PYCARD/ASC filament
FT                   nucleation."
FT                   /evidence="ECO:0000269|PubMed:24630722"
FT   MUTAGEN         136..143
FT                   /note="YRKKYRKY->FRKKFRKF: Decreased phosphorylation by
FT                   BTK; when associated with F-168."
FT                   /evidence="ECO:0000269|PubMed:34554188"
FT   MUTAGEN         143
FT                   /note="Y->R: Decreased ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36142182"
FT   MUTAGEN         147
FT                   /note="R->E: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         152
FT                   /note="E->R: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         155
FT                   /note="N->A: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         157
FT                   /note="R->E: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         166
FT                   /note="K->E: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         168
FT                   /note="Y->F: Decreased phosphorylation by BTK; when
FT                   associated with 136-F--F-143."
FT                   /evidence="ECO:0000269|PubMed:34554188"
FT   MUTAGEN         176
FT                   /note="E->R: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         198
FT                   /note="S->A: Abolished phosphorylation by MAPK8/JNK1;
FT                   decreased activation of the NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:27929086"
FT   MUTAGEN         198
FT                   /note="S->D,E: Mimicks phosphorylation state; increased
FT                   activation of the NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:27929086"
FT   MUTAGEN         213
FT                   /note="D->R: Does not affect ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         228
FT                   /note="A->Q: Abolished binding to small-inhibitor MCC950
FT                   and ability to activate the NLRP3 inflammasome following
FT                   stimulation with nigericin."
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MUTAGEN         231..233
FT                   /note="GKT->AAA: In Walker A mutant; abolished ATPase
FT                   activity. Reduced ATP-binding leading to decreased
FT                   activation of the NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:17483456,
FT                   ECO:0000269|PubMed:31086327"
FT   MUTAGEN         302..306
FT                   /note="DGFDE->AGFAA,AGFNA: In Walker B mutant; abolished
FT                   ATPase activity. Abolished binding to small-inhibitor
FT                   MCC950."
FT                   /evidence="ECO:0000269|PubMed:31086327,
FT                   ECO:0000269|PubMed:31086329"
FT   MUTAGEN         351
FT                   /note="R->T: Abolished binding to small-inhibitor MCC950
FT                   and ability to activate the NLRP3 inflammasome following
FT                   stimulation with nigericin."
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MUTAGEN         359
FT                   /note="Q->A,R: Does not affect ability to activate the
FT                   NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953,
FT                   ECO:0000269|PubMed:36442502"
FT   MUTAGEN         359
FT                   /note="Q->A: Decreased interaction with HSPA8/HSC70 and
FT                   NLRP3 degradation by the chaperone-mediated autophagy
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MUTAGEN         364
FT                   /note="H->E: Does not affect ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         424
FT                   /note="Q->A: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         509
FT                   /note="Q->A: Impaired ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:36442502"
FT   MUTAGEN         578
FT                   /note="R->A: Abolished binding to small-inhibitor MCC950
FT                   and ability to activate the NLRP3 inflammasome following
FT                   stimulation with nigericin."
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MUTAGEN         603
FT                   /note="Q->A: Decreased interaction with HSPA8/HSC70 and
FT                   NLRP3 degradation by the chaperone-mediated autophagy
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MUTAGEN         619..621
FT                   /note="KKL->EEA: Does not affect autoinhibition of the
FT                   protein."
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MUTAGEN         638..640
FT                   /note="QEE->RRR: Strongly decreased ability to activate the
FT                   NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         689..698
FT                   /note="Missing: Loss of autoinhibition of the protein."
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MUTAGEN         689
FT                   /note="K->R: Abolished ubiquitination by the SCF(FBXL2)
FT                   complex."
FT                   /evidence="ECO:0000269|PubMed:26037928"
FT   MUTAGEN         707
FT                   /note="V->R: Decreased ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         735
FT                   /note="S->A: Does not affect activation of the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   MUTAGEN         745
FT                   /note="E->R: Abolished ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         750
FT                   /note="D->R: Abolished ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         788..789
FT                   /note="FD->AR: Slightly impaired autoinhibition of the
FT                   protein; when associated with A-831."
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MUTAGEN         788
FT                   /note="F->E: Slightly decreased ability to activate the
FT                   NLRP3 inflammasome; when associated with E-813."
FT                   /evidence="ECO:0000269|PubMed:36142182"
FT   MUTAGEN         789
FT                   /note="D->R: Slightly decreased ability to activate the
FT                   NLRP3 inflammasome; when associated with D-816."
FT                   /evidence="ECO:0000269|PubMed:36142182"
FT   MUTAGEN         798
FT                   /note="Q->A: Decreased interaction with HSPA8/HSC70 and
FT                   NLRP3 degradation by the chaperone-mediated autophagy
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MUTAGEN         802
FT                   /note="E->R: Abolished ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         806
FT                   /note="S->A: Abolished phosphorylation by CSNK1A1;
FT                   increased activation of the NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   MUTAGEN         806
FT                   /note="S->D,E: Mimics phosphorylation state; decreased
FT                   activation of the NLRP3 inflammasome."
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   MUTAGEN         813
FT                   /note="F->E: Slightly decreased ability to activate the
FT                   NLRP3 inflammasome; when associated with E-788."
FT                   /evidence="ECO:0000269|PubMed:36142182"
FT   MUTAGEN         816
FT                   /note="R->D: Slightly decreased ability to activate the
FT                   NLRP3 inflammasome; when associated with R-789."
FT                   /evidence="ECO:0000269|PubMed:36142182"
FT   MUTAGEN         831
FT                   /note="K->A: Slightly impaired autoinhibition of the
FT                   protein; when associated with 788-A-R-789."
FT                   /evidence="ECO:0000269|PubMed:35114687"
FT   MUTAGEN         833
FT                   /note="W->G: Does not affect ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         844
FT                   /note="C->A: Abolished palmitoylation by ZDHHC12,
FT                   preventing degradation by the chaperone-mediated autophagy
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MUTAGEN         861
FT                   /note="Y->F: Abolished phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:27043286"
FT   MUTAGEN         864
FT                   /note="E->R: Decreased ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         918
FT                   /note="Y->G: Decreased ability to activate the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:31189953"
FT   MUTAGEN         995
FT                   /note="Q->A: Decreased interaction with HSPA8/HSC70 and
FT                   NLRP3 degradation by the chaperone-mediated autophagy
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:36586411"
FT   MUTAGEN         1035
FT                   /note="S->A: Does not affect activation of the NLRP3
FT                   inflammasome."
FT                   /evidence="ECO:0000269|PubMed:34615873"
FT   CONFLICT        167
FT                   /note="R -> L (in Ref. 2; AAL78632/AAM14669/AAL14640)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323
FT                   /note="Q -> H (in Ref. 2; AAL78632/AAM14669/AAL14640)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        439
FT                   /note="T -> S (in Ref. 10; AAC39910)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        523
FT                   /note="M -> V (in Ref. 5; BAG37494)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        599
FT                   /note="K -> M (in Ref. 10; AAC39910)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        617
FT                   /note="K -> N (in Ref. 2; AAL78632/AAM14669/AAL14640)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        622..623
FT                   /note="QI -> HD (in Ref. 10; AAC39910)"
FT                   /evidence="ECO:0000305"
FT   HELIX           6..15
FT                   /evidence="ECO:0007829|PDB:3QF2"
FT   HELIX           19..30
FT                   /evidence="ECO:0007829|PDB:3QF2"
FT   STRAND          34..37
FT                   /evidence="ECO:0007829|PDB:3QF2"
FT   HELIX           43..48
FT                   /evidence="ECO:0007829|PDB:3QF2"
FT   HELIX           51..62
FT                   /evidence="ECO:0007829|PDB:3QF2"
FT   HELIX           64..77
FT                   /evidence="ECO:0007829|PDB:3QF2"
FT   HELIX           81..89
FT                   /evidence="ECO:0007829|PDB:3QF2"
FT   HELIX           135..147
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           165..167
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          172..175
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           205..207
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          208..210
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   TURN            217..220
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          221..225
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           232..244
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   TURN            248..252
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          254..260
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           261..263
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          266..270
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           272..278
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          280..284
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           287..290
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           294..296
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          297..302
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           304..306
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          308..313
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          322..327
FT                   /evidence="ECO:0007829|PDB:8ETR"
FT   HELIX           328..336
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          340..343
FT                   /evidence="ECO:0007829|PDB:7ZGU"
FT   STRAND          344..350
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           352..354
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           355..359
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          363..372
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           375..385
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          386..388
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           389..401
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           403..408
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           412..427
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          428..430
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           439..449
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   TURN            452..454
FT                   /evidence="ECO:0007829|PDB:7ZGU"
FT   HELIX           466..478
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          482..485
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           486..491
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           496..498
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   TURN            499..501
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           502..506
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          508..510
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          513..516
FT                   /evidence="ECO:0007829|PDB:7ZGU"
FT   STRAND          517..521
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           523..534
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           558..563
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          564..566
FT                   /evidence="ECO:0007829|PDB:7ZGU"
FT   TURN            568..571
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           574..584
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           591..593
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           598..616
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          621..623
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           627..636
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           640..647
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   STRAND          652..657
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           660..671
FT                   /evidence="ECO:0007829|PDB:7ALV"
FT   HELIX           672..674
FT                   /evidence="ECO:0007829|PDB:8ETR"
FT   STRAND          679..683
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           727..739
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          745..747
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           754..765
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          774..776
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           784..796
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          802..804
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           811..822
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          824..826
FT                   /evidence="ECO:0007829|PDB:7ZGU"
FT   STRAND          831..833
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           844..851
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          859..861
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           868..879
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          888..890
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           901..910
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          916..918
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           925..936
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          938..940
FT                   /evidence="ECO:0007829|PDB:7ZGU"
FT   STRAND          945..947
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           955..957
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           958..967
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          973..975
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           983..993
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          1002..1004
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   HELIX           1012..1024
FT                   /evidence="ECO:0007829|PDB:7VTP"
FT   STRAND          1028..1031
FT                   /evidence="ECO:0007829|PDB:7VTP"
SQ   SEQUENCE   1036 AA;  118173 MW;  4C1DFB2B5B283CE8 CRC64;
     MKMASTRCKL ARYLEDLEDV DLKKFKMHLE DYPPQKGCIP LPRGQTEKAD HVDLATLMID
     FNGEEKAWAM AVWIFAAINR RDLYEKAKRD EPKWGSDNAR VSNPTVICQE DSIEEEWMGL
     LEYLSRISIC KMKKDYRKKY RKYVRSRFQC IEDRNARLGE SVSLNKRYTR LRLIKEHRSQ
     QEREQELLAI GKTKTCESPV SPIKMELLFD PDDEHSEPVH TVVFQGAAGI GKTILARKMM
     LDWASGTLYQ DRFDYLFYIH CREVSLVTQR SLGDLIMSCC PDPNPPIHKI VRKPSRILFL
     MDGFDELQGA FDEHIGPLCT DWQKAERGDI LLSSLIRKKL LPEASLLITT RPVALEKLQH
     LLDHPRHVEI LGFSEAKRKE YFFKYFSDEA QARAAFSLIQ ENEVLFTMCF IPLVCWIVCT
     GLKQQMESGK SLAQTSKTTT AVYVFFLSSL LQPRGGSQEH GLCAHLWGLC SLAADGIWNQ
     KILFEESDLR NHGLQKADVS AFLRMNLFQK EVDCEKFYSF IHMTFQEFFA AMYYLLEEEK
     EGRTNVPGSR LKLPSRDVTV LLENYGKFEK GYLIFVVRFL FGLVNQERTS YLEKKLSCKI
     SQQIRLELLK WIEVKAKAKK LQIQPSQLEL FYCLYEMQEE DFVQRAMDYF PKIEINLSTR
     MDHMVSSFCI ENCHRVESLS LGFLHNMPKE EEEEEKEGRH LDMVQCVLPS SSHAACSHGL
     VNSHLTSSFC RGLFSVLSTS QSLTELDLSD NSLGDPGMRV LCETLQHPGC NIRRLWLGRC
     GLSHECCFDI SLVLSSNQKL VELDLSDNAL GDFGIRLLCV GLKHLLCNLK KLWLVSCCLT
     SACCQDLASV LSTSHSLTRL YVGENALGDS GVAILCEKAK NPQCNLQKLG LVNSGLTSVC
     CSALSSVLST NQNLTHLYLR GNTLGDKGIK LLCEGLLHPD CKLQVLELDN CNLTSHCCWD
     LSTLLTSSQS LRKLSLGNND LGDLGVMMFC EVLKQQSCLL QNLGLSEMYF NYETKSALET
     LQEEKPELTV VFEPSW
//